<SEC-DOCUMENT>0000886163-14-000058.txt : 20140522
<SEC-HEADER>0000886163-14-000058.hdr.sgml : 20140522
<ACCEPTANCE-DATETIME>20140522160342
ACCESSION NUMBER:		0000886163-14-000058
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20140521
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140522
DATE AS OF CHANGE:		20140522

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		14863730

	BUSINESS ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		11119 NORTH TORREY PINES ROAD
		STREET 2:		SUITE 200
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgnd-viking8k.htm
<DESCRIPTION>VIKING 8K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>LGND-Viking8K</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s87782EFA4C0E48589F7D2131FAB8274F"></a><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><br><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">FORM 8&#8209;K</font></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date of Report (Date of earliest event reported): May 21, 2014</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:16pt;"><font style="font-family:inherit;font-size:16pt;font-weight:bold;">LIGAND PHARMACEUTICALS INCORPORATED </font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:8pt;">(Exact Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10.5pt;"><font style="font-family:inherit;font-size:10.5pt;font-weight:bold;">______________</font></div><div style="line-height:120%;padding-top:21px;text-align:left;text-indent:108px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware&#160;&#160;&#160;&#160;001-33093&#160;&#160;&#160;&#160;77-0160744</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">(State or Other Jurisdiction</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">(Commission File Number)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">(I.R.S. Employer</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">of Incorporation or Organization)</font><font style="font-family:inherit;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">Identification No.)</font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11119 North Torrey Pines Road, Suite 200</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">La Jolla, California 92037</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">(Address of Principal Executive Offices) (Zip Code)</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(858)&#160;550-7500</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s Telephone Number, Including Area Code)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">N/A</font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former Name or Former Address, if Changed Since Last Report)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </font></div><div style="line-height:180%;text-align:left;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#32;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </font></div><div style="line-height:120%;"><hr></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 1.01    Entry into a Material Definitive Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Master License Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 21, 2014, Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221; or &#8220;Ligand&#8221;) and its wholly owned subsidiary, Metabasis Therapeutics, Inc. (&#8220;Metabasis&#8221;) entered into a Master License Agreement with Viking Therapeutics, Inc. (&#8220;Viking&#8221;), pursuant to which, among other things, Ligand and Metabasis granted to Viking an exclusive, perpetual, irrevocable, worldwide, royalty-bearing right and license under patents related to our FBPase, SARM, TR-Beta, EPOR and DGAT-1 programs, related know-how and physical quantities of program compounds, collectively, the Licensed Technology, to research, develop, manufacture, have manufactured, use and commercialize the Licensed Technology in and for all uses in humans or animals.  Viking will be responsible for research, development, manufacturing and commercialization activities, including all regulatory filings, and has the right to sublicense its rights in certain circumstances.  The license grant to our FBPase program will automatically terminate if Viking does not exercise an exclusive option it has to the FBPase program prior to March 28, 2015.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FBPase licensed products are selective inhibitors of fructose-1,6-bisphosphatase, which may provide an alternative approach to controlling blood glucose levels in patients with diabetes.  The SARM licensed products are non-steroidal selective androgen receptor modulators that may produce the therapeutic benefits of testosterone with improved safety, tolerability and patient acceptance due to a tissue-selective mechanism of action and an oral route of administration.  The TR-Beta licensed products are TR&#946; agonists that specifically target liver tissue, the major site of cholesterol metabolism.  The EPOR licensed products include small molecule agonists of the erythropoietin receptor for the potential treatment of anemia.  The DGAT-1 licensed products include small molecule inhibitors of the enzyme diacylglycerol acyltransferase-1 for the potential treatment of lipid disorders such as obesity and chylomicronemia. Rights to the FBPase, TR-Beta and DGAT-1 licensed programs were acquired pursuant to Ligand&#8217;s acquisition of Metabasis.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The upfront payments under the Master License Agreement consist of shares of Viking capital stock.  If Viking completes an initial public offering, Viking will issue to Ligand and Metabasis a number of shares of Viking common stock having an aggregate value of $29,000,000, subject to adjustment in certain circumstances.  Ligand and Metabasis have the option to receive a number of shares of the same class and type of securities issued and sold by Viking in a private financing which occurs prior to an IPO having an aggregate value of $29,000,000, subject to adjustment in certain circumstances, or, in lieu of receiving the same class and type of shares issued in the private financing, to defer its right to receive equity in Viking until an IPO or subsequent private financing of Viking.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Viking also agreed to pay Ligand and/or Metabasis certain one-time, non-refundable milestone payments in connection with licensed products containing (1) any licensed FBPase compound, in an aggregate amount of up to $60,000,000 per indication (for up to a total of four indications) upon the achievement of certain development and regulatory milestones and up to $150,000,000 upon the achievement of certain sales milestones, (2) any licensed SARM compound, in an aggregate amount of up to $85,000,000 per indication (for up to a total of two indications) upon the achievement of certain development and regulatory milestones and up to $100,000,000 upon the achievement of certain sales milestones, (3) any licensed TR-Beta compound, in an aggregate amount of up to $75,000,000 per indication (for up to a total of three indications) upon the achievement of certain development and regulatory milestones and up to $150,000,000 upon the achievement of certain sales milestones, (4) any licensed EPOR compound, in an aggregate amount of up to $48,000,000 per indication (for up to a total of three indications) upon the achievement of certain development and regulatory milestones and up to $50,000,000 upon the achievement of certain sales milestones, and (5) any licensed DGAT-1 compound, in an aggregate amount of up to $78,000,000 per indication (for up to a total of two indications) upon the achievement of certain development and regulatory milestones and up to $150,000,000 upon the achievement of certain sales milestones.  Additionally, Viking will pay Metabasis a one-time, non-refundable milestone payment of $2,500,000 upon the occurrence of the first commercial sale of any licensed FBPase compound by a Viking sublicensee.  Viking will also pay to Ligand and/or Metabasis royalties on aggregate annual worldwide net sales of licensed products at tiered percentage rates in the following ranges based upon net sales: (a) upper single digit royalties upon sales of any licensed FBPase compound, (b) upper single digit royalties upon sales of any licensed SARM compounds, (c) low-to-middle single digit royalties upon sales of any licensed TR-Beta compounds, (d) middle-to-upper single digit royalties upon sales of any EPOR licensed compounds, and (e) low-to-middle single digit royalties upon sales of any DGAT-1 licensed compounds; in each case subject to reduction in certain circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ligand has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (1) if, on or before April 30, 2015, Viking has neither (a) completed an IPO nor (b) received aggregate net proceeds of at least $20,000,000 in one or more private financings, (2) in the event of Viking&#8217;s insolvency or bankruptcy, (3) if Viking does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, and (4) if Viking defaults on certain material obligations and fail to cure the default within a specified period of time.  Viking has the right to terminate the Master License Agreement under certain circumstances, including, but not limited to: (a) if Ligand does not pay an undisputed amount owing under the Master License Agreement when due and fails to cure such default within a specified period of time, and (b) if Ligand defaults on certain of its material obligations and fails to cure the default within a specified period of time.  In addition, provisions of the Master License Agreement can be terminated on a licensed program-by-program basis under certain circumstances.  In the event that the Master License Agreement is terminated in its entirety or with respect to a specific licensed program for any reason: (i) all licenses granted to Viking under the Master License Agreement (or with respect to the specific licensed program) will terminate and Viking will, upon Ligand&#8217;s request, assign and transfer to Ligand, at no cost to Ligand, all regulatory documentation and all regulatory approvals to the extent related to the Licensed Products (or those related to the specific licensed program; and (ii) Viking will grant to Ligand a non-exclusive, worldwide, royalty-bearing sublicensable license under any Viking-controlled patent rights and know-how to the extent necessary to make, have made, import, use, offer to sell and sell the Licensed Products (or those related to the specific licensed program) anywhere in the world at a royalty rate in the low single digits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Master License Agreement, Ligand and Viking entered into a Loan and Security Agreement, dated May 21, 2014, or the Loan and Security Agreement, pursuant to which, among other things, Ligand agreed to provide Viking with loans in the aggregate amount of up to $2,500,000.  Ligand will initially loan $1,000,000 to Viking no later than May 27, 2014, and has agreed to loan an additional $250,000 each month beginning in June 2014 through and including November 2014.  The principal amount outstanding under the loans accrues interest at a fixed per annum rate equal to the lesser of 5% and the maximum interest rate permitted by law, with a higher interest rate in the event of a Viking default.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loans are evidenced by a Secured Convertible Promissory Note, or the Note.  Pursuant to the terms of the Loan and Security Agreement and the Note, the loans will become due and payable upon the written demand of Ligand at any time after the earlier to occur of an event of default under the Loan and Security Agreement or the Note, and May 21, 2016, unless the loans are converted into equity prior to such time.  Upon the consummation of the earlier to occur of: (1) a bona fide capital financing transaction or series of financing transactions with one or more financial non-strategic investors with aggregate net proceeds to Viking of at least $20,000,000 and pursuant to which Viking issues shares of its equity securities; and (2) an IPO; Ligand may elect either to (a) receive such number of shares of the type of equity which Viking issues in the private financing or the IPO equal to 200% of the amount obtained by dividing the entire then-outstanding principal amount of the loans, plus all accrued and previously unpaid interest thereon, by the lowest per share price paid by investors in the private or public offering, or (b) require Viking to prepay an amount equal to 200% of the principal amount of the loans then-outstanding plus all accrued and previously unpaid interest thereon, or the Prepayment.  Moreover, if a private financing occurs prior to an IPO and Ligand has not elected to receive shares of the type of equity Viking issues in the private financing or to receive the Prepayment, Ligand may elect to extend the maturity date to a mutually agreed date.  Furthermore, if a change of control of Viking occurs prior to the earlier of the maturity date or issuance of Viking securities as described above, Ligand may elect to either receive a specified number of shares of Viking securities equal to 200% of the amount obtained by dividing the entire then-outstanding principal amount of the loans, plus all accrued and previously unpaid interest thereon, by the lowest per share price set forth in the Loan and Security Agreement or require Viking to make the Prepayment.  The loans are secured by all of Viking&#8217;s assets. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An event of default under the Loan and Security Agreement will be deemed to occur or exist upon the termination of the Master License Agreement; in the event Viking fails to make principal or interest payments under the Note when due; if Viking becomes insolvent or breaches and fail to cure within a specified period of time any representation, warranty, covenant or agreement in the Loan and Security Agreement, the Master License Agreement and other specified agreements between Viking and Ligand; and upon the occurrence of certain other events.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Management Rights Letter; Voting Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Master License Agreement, the Company entered into a Management Rights Letter with Viking on May 21, 2014 (the &#8220;Management Rights Letter&#8221;), pursuant to which the Company is entitled to appoint one director to the board of directors of Viking, which will initially be Matthew W. Foehr, the Company&#8217;s Executive Vice President and Chief Operating Officer. Under the Management Rights Letter, the Company will also have certain continuing information and consultation rights in the event the Company is no longer represented on the board of directors of Viking.  The Management Rights Letter will terminate upon the earliest to occur of certain corporate transactions by Viking, the date after a Qualified Financing that Ligand and its affiliates own less than 7.5% of the outstanding voting securities of Viking, or May 21, 2024.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Management Rights Letter, certain stockholders of Viking agreed to vote the voting securities of Viking which they hold in support of the Company&#8217;s representative on the Viking board of directors. This agreement will terminate under the same circumstances as the Management Rights Letter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Registration Rights </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Viking has agreed to provide for the resale of any shares of Viking securities that may be issued to Ligand or Metabasis under the Master License Agreement or the Loan and Security Agreement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Sublease Agreement</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 21, 2014, we entered into a Sublease and Services Agreement with Viking for approximately 5,851 square feet of individual and shared space within our offices.  We agreed to provide Viking with research and development, professional, human resources, administrative, information technology and general office services during some or all of the sublease term for a fee.  The sublease commences immediately and has a term of seven months, with Viking retaining the right to terminate the sublease upon 45 days written notice in certain circumstances.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing summary of the terms of the Master License Agreement and the Loan and Security Agreement does not purport to be complete and is qualified in its entirety by reference to the Master License Agreement and the Loan and Security Agreement, copies of which will be filed with the Securities and Exchange Commission by Ligand with its Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2014.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In anticipation of the transactions with Viking described above, on May 20, 2014, Ligand entered into an Amendment of &#8220;General&#8221; Contingent Value Rights Agreement and an Amendment of &#8220;TR Beta&#8221; Contingent Value Rights Agreement, each with David F. Hale, as Stockholders&#8217; Representative, and Computershare Inc. (as successor to Mellon Investor Services LLC) as Rights Agent (collectively, the &#8220;CVR Amendments&#8221;).  A description of the CVR Amendments is contained in a Current Report on Form 8-K filed by Ligand on May 22, 2014, which is incorporated by reference herein, and pursuant to which copies of the CVR Amendments were filed with the Securities and Exchange Commission.     </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with Mr. Foehr&#8217;s service as the Company&#8217;s designee on Viking&#8217;s board of directors, Mr. Foehr may become entitled to compensation from Viking for such service.  Pursuant to a letter agreement between Mr. Foehr and the Company, Mr. Foehr will be entitled to retain any cash compensation paid to him by Viking for his service as  non-employee director of Viking.  Mr. Foehr will, however, be obligated to transfer to the Company any equity compensation paid to him by Viking for his service as a non-employee director of Viking or, if such transfer is not permissible under the terms of Viking&#8217;s equity plan, to exercise such equity awards at the direction of the Company and immediately thereafter transfer the shares issued upon exercise of such equity awards to the Company.  The Company will reimburse Mr. Foehr for any taxes payable by him in connection with the exercise of such equity awards.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The foregoing summary of the terms of the letter agreement between the Company and Mr. Foehr does not purport to be complete and is qualified in its entirety by reference to the letter agreement, a copy of which will be filed with the Securities and Exchange Commission by Ligand with its Quarterly Report on Form 10-Q for the fiscal quarter ending June 30, 2014.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 7.01    Regulation FD Disclosure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 22, 2014, Ligand issued a press release entitled &#8220;Ligand Licenses Five Programs to Viking Therapeutics .&#8221; A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The information in this Item 7.01, including the press release attached hereto as Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 9.01    Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(d)&#160;&#160;&#160;&#160;Exhibits.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="14%"></td><td width="86%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 22, 2014.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:26px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;padding-bottom:48px;text-align:left;padding-left:240px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="line-height:120%;padding-left:25px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="42%"></td><td width="58%"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:16px;padding-right:2px;"><div style="padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: May 22, 2014</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:   </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Charles S. Berkman</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:inherit;font-size:10pt;">Name:   Charles S. Berkman <br>Title:   Vice President, General Counsel and Secretary</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="14%"></td><td width="86%"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated May 22, 2014.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><br><div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>gnd-vikingpressrelease.htm
<DESCRIPTION>EXHIBIT-PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>LGND-VikingPressRelease</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="sB3D43A333DCF161188CE2132FD9E552C"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;"><img src="ligandlogoa05.jpg" style="font-size:12pt;font-weight:bold;height:69px;width:196px;"></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contacts:</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ligand Pharmaceuticals Incorporated&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LHA</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">John Higgins, President and CEO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bruce Voss </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">investors@ligand.com &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;bvoss@lhai.com     </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(858) 550-7500&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(310) 691-7100&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">@Ligand_LGND&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;@LHA_IR_PR</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ligand Licenses Five Programs to Viking Therapeutics</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Invests $2.5 million in Viking via a convertible loan facility</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SAN DIEGO (May 22, 2014) &#8211; Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)</font><font style="font-family:inherit;font-size:12pt;">&#32;announces the licensing of rights to five programs to Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The therapeutic programs covered in the license agreement include Ligand's FBPase inhibitor program for type 2 diabetes, a Selective Androgen Receptor Modulator (SARM) program for muscle wasting, a Thyroid Hormone Receptor-&#946; (TR&#946;) Agonist program for dyslipidemia, an Erythropoietin Receptor (EPOR) Agonist program for anemia, and an Enterocyte-Directed Diacylglycerol Acyltransferase-1 (DGAT-1) Inhibitor program for dyslipidemia. The FBPase Inhibitor program was the subject of an option originally granted to Viking in 2012.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each licensed program includes a fee to be paid to Ligand in Viking equity at the time of a private or public financing, milestone payments and royalties on future net sales.  Viking is responsible for all development activities under the license.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As part of this transaction, Ligand has agreed to extend a $2.5 million convertible loan facility to Viking that can be used to pay Viking&#8217;s operating and financing-related expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">"This is a creative licensing transaction that combines a bold portfolio of early- and mid-stage assets with a company that can advance these programs to major inflection points in the near-term.  Viking&#8217;s programs have the potential to generate substantial news flow over the next 12 to 24 months and to be the basis for important new drugs in major therapeutic categories," said John Higgins, President and CEO of Ligand Pharmaceuticals.  </font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">"R&amp;D success has been the backbone of our prolific out-licensing activities over the past few years.  Our objective is to establish proof-of-concept and solid initial data packages, and then to partner with companies that are well-positioned to manage advanced clinical and regulatory development.  A relationship such as this one with Viking gives Ligand the opportunity to entrust valuable internal programs to a dedicated team with the operational resources to take them to the next level.  Each of these licensed programs has the hallmark of quality that has defined Ligand's successful research </font></div><br><div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB3D43A333DCF161188CE2132FD9E552C"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">heritage over the years.  We are pleased to have helped establish a platform to advance the programs and to make this investment in Viking to support further progress," Higgins continued.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Along with our partners at Ligand, we have created through this license an excellent vehicle to develop several promising new therapies for patients, while unlocking potential value for stakeholders,&#8221; said Brian Lian, President and CEO of Viking Therapeutics.  &#8220;Each of the licensed programs has what we believe to be first-in-class or best-in-class characteristics and a differentiated therapeutic profile.  Importantly, the portfolio fits well within Viking&#8217;s focus, as our team has an extensive history in diabetes and endocrine drug development, including two recent drug approvals.  At all levels, from preclinical through pharmaceutical development, and including our chief medical officer, we have well-aligned development expertise to bring these programs forward.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Viking Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders.&#160; Viking&#8217;s research and development activities leverage its expertise in metabolism to develop innovative therapeutics that improve patients&#8217; lives. &#160;Viking has a portfolio of five drug candidates in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand and its affiliate.  Viking&#8217;s lead clinical program is VK0612, a first-in-class, orally available drug candidate for type 2 diabetes (Phase 2b). &#160;Viking&#8217;s second clinical program is VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, for the treatment of cancer cachexia (Phase 2).  Viking is also developing three novel preclinical programs targeting metabolic diseases and anemia.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For additional information about Viking and its programs, please visit www.vikingtherapeutics.com.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">About Ligand Pharmaceuticals </font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand&#8217;s goal is to produce a bottom line that supports a sustainably profitable business.  By diversifying our portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand&#8217;s Captisol platform technology is a patent protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Eli Lilly &amp; Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol. For more information on Ligand, please visit www.ligand.com.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Follow Ligand on Twitter @Ligand_LGND.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forward-Looking Statements</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. These statements include those related to Viking equity payable to Ligand at the time of a private or public financing, future milestone </font></div><br><div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sB3D43A333DCF161188CE2132FD9E552C"></a><div><div style="line-height:180%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><br><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">payments and royalties, and potential future news flow, new therapies and market potential relating to licensed product candidates. Actual events or results may differ from our expectations. There can be no assurance that Viking will complete a private or public financing resulting in the upfront equity payment to Ligand, that Viking will continue clinical development of any product candidates; that preclinical or clinical development will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that products will receive required regulatory approvals or that they will be commercially successful, that any future milestone or royalty payments will be received, or that if any future equity, milestones or royalties are received that they will not be subject to sharing obligations with any third party.  Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting Ligand's business can be found in the company's prior press releases as well as in public periodic filings with the Securities and Exchange Commission, available at www.ligand.com. Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"># # #</font></div><br><div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:180%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ligandlogoa05.jpg
<TEXT>
begin 644 ligandlogoa05.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X0!817AI9@``34T`*@````@`!`$Q``(`
M```1````/E$0``$````!`0```%$1``0````!```N(U$2``0````!```N(P``
M``!!9&]B92!);6%G95)E861Y``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"`(+!<8#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`KB-?\`B-;Z;=SV5C:-<3Q,T;R2':BN..!U8`Y!Z=.#SFNWKYQH
M`ZR[^(WB"YV>5);VNW.?)A!W?7?N_3'6J_\`PGOB7_H)?^0(_P#XFN;HI@=)
M_P`)[XE_Z"7_`)`C_P#B:DM_B#XCAG622[CG49S')"H4\=]H!_6N7HH`],TG
MXGQ2/'%JMGY6>&G@)*@Y[H>0`.N"3QTYKT".1)HDEB=7C=0RLIR&!Z$'N*^<
MZ]M\#2/+X,TYI'9V"NH+')P'8`?0``?A2`Z&BBB@`HHHH`****`(+R\M["TE
MNKJ58H(EW.[=`/ZGV[UY;KGQ'U"^WPZ:GV*W.1YG65AR.O1>".G((^]5+QMX
MDEUK5I+>&;.GVSE8E4C#L."^03GG.#Z>F3G8\*^$[*'1)/$&M0M-&L;3Q6V"
M,(O.X@XW$XX!XP><YX`.7M=$U_Q#*;F*UNKIG7=]HE;`<#Y?OL<$CIC/;VJS
M)X&\211/(VF,512Q"RHQP/0!LD^PKN/^%GZ+_P`^NH?]^T_^+H_X6?HO_/KJ
M'_?M/_BZ8'`V.NZ[X;N5@2:XA\K@VEP#M`)#8V'IGU&#SUYKTGPKXUM_$#?9
M;B-;:_"Y"!LK*`.2OH>OR\\=SSB21=`\?:6`LC,8F!RORRP$C..0>#T[@XXY
M&1Y3JVFW?A[69+:0R1R0ONAE'REES\KK@\=/7@\=10![Y17/>#?$!U_1%DG=
M3>0-Y<X``R>S8!Z$?3D-@<44@.AHK-U37]*T;:-0O8X6;&$Y9B#GG:,G'!YQ
MBN>D^)NAI*Z+#?2*K$!UC7##U&6!Q]0*`.SHKSJ3XJH)7$6CLT88[6:XVDCL
M2-IP?;)IO_"UO^H+_P"37_V%`'H]%<':_%+3GB)N]/NHI-W"Q%9!CUR2O/7C
M%;-AXZ\/W_EK]M^SROGY+A2FW&>K?='3U_7B@#HZ***`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"OG&OHZOG&@`HHHI@%%%
M%`!7M?@+_D2]/_[:?^C&KQ2O:_`7_(EZ?_VT_P#1C4`='1112`****`"L?Q7
M?OIOA?4+J+=Y@CV*5;:5+$*&!]1NS^%;%<YX]_Y$O4/^V?\`Z,6@#RCPYIHU
M;Q%8V3A3')(#(&)`*+\S#(YR0"*]H\0_\BUJO_7G-_Z`:\G\!?\`(Z:?_P!M
M/_1;5ZQXA_Y%K5?^O.;_`-`-`'CWA&PMM4\3V=G>1>;;R;]Z;BN<(Q'((/4"
MNQ\8>"M(L="EO[$?8WM^6!9W60$@;><D')&#TYY]1YY8?;?ML?\`9WVC[7SY
M?V?=OZ'.-O/3/X59U;^V_P!S_;']H?Q>5]LW^V=N[\,X]J8&IX`D=/&=DJ.R
MJZR*X!P&&QC@^HR`?P%==\3-)6XTF'4XX_WMLX21A@?NV]>YPV,>FXU2^&+Z
M47G189%U548M(S$J\1*]!T&"!UYYZ]ATGCW_`)$O4/\`MG_Z,6D!YQX-\10>
M'=3GFNA</;RP[#'#@Y;(()!('`W?G[T5S=%,">\O+B_NY;JZE:6>5MSNW4G^
M@]NU0444`%%%%`!1110!ZI\,=2EN=)NM/D&5M'!C;C[KY.W&.Q!.?]KVKNJ\
MX^%/_,7_`.V/_L]>CT@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"OG&OHZOG&@`HHHI@%%%%`!7M?@+_`)$O3_\`MI_Z,:O%
M*]K\!?\`(EZ?_P!M/_1C4`='1112`****`"J6L6/]IZ->606,M-"R)Y@^4-C
MY2?H<'\*NT4`?/5O-/I>IQ3>7MN+68/Y<BD893G##@]1S7M6HWT&I^"KZ]MV
MS%-82NO(R/D/!QW!X/N*X_Q]X1E6>;6[!-\;?-<Q*H!0XY<8Z@]3W!R>A..;
M\,^)I="G>&9/M&FW'%Q;,`001@L`>,X[=".#V(8$O@+_`)'33_\`MI_Z+:O1
M_'5A]O\`"5WMBWRV^)T^;&W:?F/7GY2W']<4S1=1\(W30W&GIIMO<E@J*8DB
ME#$?=`X)/..,@\C)K=OKBRM[9O[0FMXK>3]V?M#*JMD'Y>>#D9XI`>-^![P6
M?B^Q9Y6CCE9HFQG#%E(4''4;MOZ'M72?$_6$=K;1X]K,C>?,>I4X(4=>#@DD
M$=UIOB3Q'X9M8);;1]*T^>[/R^?]D3RX^2"1D?,>./X><Y/0\9INFW_B#5!;
MVX::XE8N\CDD`9Y=CZ<]?YDTP.J^&^B0:A<WMY>6T<UO&@B1)H0ZLQ.203QD
M`#_OK\RO1=%TFWT32X;&W5<(HWN%P9'QRQZ\GZ\<#H**0'@%%%%,`HHHH`**
M**`/1_A3_P`Q?_MC_P"SUZ/7G'PI_P"8O_VQ_P#9Z]'I`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%?.-?1U?.-`!1113`**
M**`"O:_`7_(EZ?\`]M/_`$8U>*5[7X"_Y$O3_P#MI_Z,:@#HZ***0!1110`4
M444`%<9X@^'EAJ3/<:<RV-QM_P!6J#RF(![#[I/'(].A)KLZ*`/&[KX=^(;>
M4)%;PW*E<[XIE`!]/FVG/X=ZA_X0+Q+_`-`W_P`CQ_\`Q5>U44`>5Z3\,]0N
M'CDU.>.UBZM'&=\G7I_=&1GG)QQQ7HNDZ+8:):+;V,"H-H#R$#?(1GECW/)^
MF>,"K]%`!1110!\XT444P"BBB@`HHHH`]'^%/_,7_P"V/_L]>CUYQ\*?^8O_
M`-L?_9Z]'I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`52O]7T_3%)O+N*
M(@!MA.6()QD*.3^5<;XM\6S?:)--TV1XA$^V:9258L#]U3U`!ZGO].O$5Y.)
MS14Y.%-7\^A[&%RJ52*G4=D^G4]5F\;:%%$SI<O,PZ(D3`G_`+Z`'ZU4_P"%
MA:3_`,^][_WPG_Q5>:T5PO-<0]K+Y'='*<.M[OYGJL/C;0I8E=[EX6/5'B8D
M?]\@C]:U+#5]/U-0;.[BE)!;8#A@`<9*GD?E7BU%:0S>JG[T4_P(GD])KW9-
M?B>[45P'A+Q;-]HCTW4I'E$K[89F)9@Q/W6/4@GH>WTZ=_7LX?$0KPYHGB8G
M#3P\^284445N<X4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_P`B7I__`&T_]&-7BE>U^`O^
M1+T__MI_Z,:@#HZ***0!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`*
M***`"BBB@#T?X4_\Q?\`[8_^SUZ/7G'PI_YB_P#VQ_\`9Z]'I`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!6=KM^=-T.\NU+!TCPA4`X8\*<'W(K1KE_'TTD7AU
M41L++.J.,=1@MC\U'Y5AB9N%&4EV-\-!5*T8OJSS&BBBOD#[,****`"BBB@`
MKVO2[S^T-*M;LE"TL2LVP\!L<C\#D?A7BE>L^#?^13LO^VG_`*&U>ME$FJLH
M^7]?F>/G,4Z49=G^?_#&[1117T!\Z%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`5\XU]'5\XT`%%%%,`HHHH`*]K\!?\B7I_P#V
MT_\`1C5XI7M?@+_D2]/_`.VG_HQJ`.CHHHI`%%%%`!1110`4444`%%%%`!11
M10`4444`?.-%%%,`HHHH`****`/1_A3_`,Q?_MC_`.SUZ/7G'PI_YB__`&Q_
M]GKT>D`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%<G\0O\`D`0?]?2_^@O765S'
MCRW>?PV9%*@03)(V>XY7C\6%<N-3>'G;L=6":6(A?N>84445\F?8!1110`44
M44`%>G>`89(O#K.ZX66=G0YZC`7/YJ?RKS&O6O!Z/'X5L5=64D.V&&."[$'\
M00:]/*8WKM]E_D>5F\K4$N[_`,S<HHHKZ,^:"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`*^<:^CJ^<:`"BBBF`4444`%>U^`O^
M1+T__MI_Z,:O%*]K\!?\B7I__;3_`-&-0!T=%%%(`HHHH`****`"BBB@`HHH
MH`****`"BBB@#YQHHHI@%%%%`!1110!Z/\*?^8O_`-L?_9Z]'KSCX4_\Q?\`
M[8_^SUZ/2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBLW_A(=%_Z#&G_^!*?XT`:5%8%QXV\.6T[0R:I&67&3&C2+TSPR
M@@_G4?\`PGOAK_H)?^0)/_B:`.CHKGH_'/AN65(UU-0SL%!:)U&3ZDK@#W-7
M_P#A(=%_Z#&G_P#@2G^-`&E13(9HKB)989$DC;HZ,"#^(I]`!1110`4444`%
M4M7L!J>DW5F0I,L9";B0`W52<>A`-7:*4HJ2<7LRHR<9*2W1X6Z/%(T<BLCJ
M2K*PP01U!%-KT;Q/X-_M"5KW30B7#9,L1.!(?4>C'\CUXYSP5YIUYI\FR\MI
M8220-ZD!L=<'H?PKY/$86I0DU):=SZ[#8NG7BG%Z]BM1117,=0445=L-(U#4
MV`L[264$E=X&%!`S@L>!^=.,7)VBKLF4HQ5Y.R*T$,ES<1P1+NED<(BYQDDX
M`YKVVUMTL[."VC+%(8UC4MU(`P,_E7/^&?"D>BYN;HI->G(#+RL8_P!G/<]S
M^'KGI:^CR["2HQ<I[L^:S+%QKR48;+\0HHHKTCS`HHHH`****`"BBB@`HHHH
M`**J76JZ=8RB*[O[6WD*[@LLRH2/7!/3@U4N/%&A6T#32:M9E5QD1RB1NN.%
M7)/Y4`:U%<Y_PGOAK_H)?^0)/_B:/^$]\-?]!+_R!)_\30!T=%85KXR\/7DI
MCBU2%6"[LRAHACZL`,\]*M_\)#HO_08T_P#\"4_QH`TJ*;'(DT22Q.KQNH96
M4Y#`]"#W%.H`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHK-_X2'1?^@QI_\`X$I_C0!I45SG_">^
M&O\`H)?^0)/_`(FC_A/?#7_02_\`($G_`,30!T=%9<?B30Y8DD75[$*ZA@&G
M53@^H)R#[&KMK>6M]$9;2YAN(PVTM%('`/ID=^10!/1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`454NM5TZQ
ME$5W?VMO(5W!99E0D>N">G!JE=>*]`LXA)+JUJREMN(G\TY^BY...M`&Q17.
M?\)[X:_Z"7_D"3_XFG1^.?#<LJ1KJ:AG8*"T3J,GU)7`'N:`.AHK-_X2'1?^
M@QI__@2G^-:5`!1110`4444`%%%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_R)
M>G_]M/\`T8U>*5[7X"_Y$O3_`/MI_P"C&H`Z.BBBD`4444`%%%%`!1110`44
M44`%%%%`!1110!\XT444P"BBB@`HHHH`]'^%/_,7_P"V/_L]>CUYQ\*?^8O_
M`-L?_9Z]'I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110!RNO>/=,T:62VB#7EVC;6CC.U4(QD,WKR>@/(P<5R<GQ0U<RN8K
M.Q6,L=JLKL0.P)W#)]\"N+N+B6[N9;B9MTLKEW;`&6)R3@>]1TP.HN/B#XCF
MG:2.[C@4XQ''"I4<=MP)_6H_^$]\2_\`02_\@1__`!-<W10!VO\`PL_6_P#G
MUT__`+]O_P#%ULZ;\4+>66./4K%H%*@--$^\;N,G;C(7J>I/UKS&B@#Z,CD2
M:))8G5XW4,K*<A@>A![BG5SG@+_D2]/_`.VG_HQJZ.D`4444`%%%%`!1110`
M4444`%%%9NLZ[I^@VPFOYMF_(CC49:0@9P!_4X'(R1F@#2K-U37]*T;:-0O8
MX6;&$Y9B#GG:,G'!YQBO+]:^(.KZIF.U;[!;G^&%OG/3J_!Z@],<'!S7)T`>
MCW_Q3_UB:=IOIY<MP_TSE%_$?>]_:N7OO&OB"_W!]1DA0OO"VX$>WKQD?,1S
MW)K`HI@27%Q/=SM-<3232MC=)(Q9C@8Y)]JCHHH`****`"BBB@`K;M/%_B"R
MW^5JMPV_&?.(EZ>F_..O:L2B@#T73?BDX8+JFGJ5+',EJ<$#'`VL>3GON'7V
MY[/2?$ND:RD?V2\C\U^/(D.V0'&2-IZX'<9'!YKP>B@#Z.HKQW1?B#J^EXCN
MF^WVX_AF;YQUZ/R>I'7/`P,5Z=H_B'3-=B#6-RK2!<M"WRR+TSE?09`R,C/>
MD!J4444`%%%%`%)]'TR61I)-.M'=B69F@4DD]23BF_V)I/\`T"[+_P`!T_PJ
M_14>SAV1?M9_S,J0Z5I]M*LL%A:Q2KT=(54CMU`JW115**CHD3*3EJV%%%%,
M04444`%%%9NJ:_I6C;1J%['"S8PG+,0<\[1DXX/.,4`:5%>8ZM\3[B1FCTFU
M6*,J1YMP-SY('(4'`(.>N[/'TKC]2US4]78F_O9IE+!MA;"`@8R%'`./0=S0
M!Z[J7C?0--4YO5N9-H81VO[PD$XZCY0>^"1_*N9O_BG_`*Q-.TWT\N6X?Z9R
MB_B/O>_M7G%%,#IKSQ]XANVEVWBV\<B[?+AC4!1C'!.6![YS]*PKO4;V_P!G
MVR\N+C9G9YTK/MSUQD\=!5:B@`HHHH`****`"BBB@`K6M_%&NVTZS1ZM>%ES
M@22F1>F.5;(/Y5DT4`=K8?$S5[?RUO(+>[1<[VQY;MUQR/E&./X>@_&NMTSX
MAZ)?;4N'DLI3M&)ERI8]<,.P/=L?SQX[10!]%6]Q!=P+-;S1S1-G;)&P93@X
MX(]ZDKY^TW5]0T><S:?=R0,?O!3E6X(Y4\'J>HXKT70?B3;WDL=MJT*VTKMM
M$\9_=9.?O`\J.@SD^IP*0'>44V.1)HDEB=7C=0RLIR&!Z$'N*=0`4444`%%%
M%`!1110`4444`<AX@^(%AHUV]G;P->W$;8DVN%1#SD;L'+#CC'?KD8KE?^%G
MZW_SZZ?_`-^W_P#BZXZXN);NYEN)FW2RN7=L`98G).![U'3`Z3_A/?$O_02_
M\@1__$U);_$'Q'#.LDEW'.HSF.2%0IX[[0#^M<O10!W5O\4=46=3<6-G)%SN
M6/<C'CL23CGVKM_#GBJP\1Q,(-T-S&H,D$A&0..5/=<\9_,#(KPZNH^'UQ+#
MXQM8XVPLR2)(,#E=I;'YJ#^%`'LU%%%(`HHHH`*;)(D,3RRNJ1HI9F8X"@=2
M3V%<=X@^(=AIK/;Z<JWUQM_UBN/*4D'N/O$<<#UZ@BO.-8\0ZGKLI:^N6:,-
ME85^6->N,+ZC)&3DX[T`>DZM\1](L'DBM$DOI5XS'\L><X(W'VYR`0>.:XJ^
M^('B"]W!+B.U1DV%;>,#UYR<L#SV(Z5R]%,">ZO+J^E$MW<S7$@7:&ED+D#T
MR>W)J"BB@`HHHH`****`-:Q\3ZWIVT6VIW`54V*CMYBJO&`%;('3L*ZC3/B?
M=Q;8]3LXYU^4&6$[&Q_$Q!R">^!M'].!HH`]ZT?Q#IFNQ!K&Y5I`N6A;Y9%Z
M9ROH,@9&1GO6I7SG'(\,J2Q.R2(P964X*D="#V-=MX?^(U[9,D&K!KNV"X$B
M@>:O`QSD!AQWYYSD]*0'JU%06=Y;W]I%=6LJRP2KN1UZ$?T/MVJ>@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`***Y/Q%X\T_1_.M;4_:K],KM`^2-N
M/O'OU/`SR"#B@#JI)$AB>65U2-%+,S'`4#J2>PKE]6^(&BZ8S10R->S!3@6^
M"@.`0"_3!SU&<8->7ZQXAU/792U]<LT8;*PK\L:]<87U&2,G)QWK+H`[/4OB
M5K%TQ%DD-E'N!!"^8^,<@EN",\_=';\>9OM8U+4]PO;ZXG4OOV/(2H;GD+T'
M4]!5*BF`4444`%%%%`!4]K>75C*9;2YFMY"NTM%(4)'ID=N!4%%`'6:9\0];
ML=J7#QWL0VC$RX8*.N&'<CNV?YY[;1?B#I&J8CNF^P7!_AF;Y#UZ/P.@'7')
MP,UX[10!]'45X9HOBO5]"PEK<;[<?\N\WS)WZ#JO))X(R>N:]4\/^+M-\0($
MC?R+L8!MY6&XG&3M_O#@^_'(%(#?HHHH`*^<:^CJ^<:`"BBBF`4444`%>U^`
MO^1+T_\`[:?^C&KQ2O:_`7_(EZ?_`-M/_1C4`='1112`****`"BBB@`HHHH`
M****`"BBB@`HHHH`^<:***8!1110`4444`>C_"G_`)B__;'_`-GKT>O./A3_
M`,Q?_MC_`.SUZ/2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@#YQHHHI@%%%%`!1110![7X"_Y$O3_^VG_HQJZ.N<\!?\B7
MI_\`VT_]&-71T@"BBB@`HHHH`****`"BBN!\;>-OL?F:5I4O^D\K/<*?]5ZJ
MI_O>I[?7H`6?%?CR#2_/T_33YM^ORM+@%(CW^K#TZ`GGH17EMY>7%_=RW5U*
MTL\K;G=NI/\`0>W:H**8!1110`4444`%%%%`!1110`4444`%%%%`!1110`5/
M9WEQ87<5U:RM%/$VY'7J#_4>W>H**`/6?"GCR#5/(T_4CY5^WRK+@!)3V^C'
MTZ$CCJ!7:U\XUZAX)\;?;/+TK59?])X6"X8_ZWT5C_>]#W^O5`=]1110`444
M4`%%%%`!1110`56OM0M-,MFN+VXC@B'\3G&3@G`'<X!X'-0ZUJ]OHFES7UPR
MX13L0M@R/CA1UY/TXY/05XEK.NZAKUR)K^;?LR(XU&%C!.<`?U.3P,DXH`ZC
MQ!\1[F^0V^D))9Q'(:9L>8P(Q@==O)/()/3D5P\DCS2O+*[/([%F9CDL3U)/
M<TVBF`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!TWACQE
M>Z!+%!*S3Z;N.Z#C*YZE#V/?'0Y/0G->PV=Y;W]I%=6LJRP2KN1UZ$?T/MVK
MYXKH?"OBJX\.7>UMTMA*W[Z$'D'^\OHW\^A[$`'MM%1V]Q%=VT5Q`VZ*5`Z-
M@C*D9!P?:I*0!1110`4444`%%%%`'SC1113`****`"ND\!?\CII__;3_`-%M
M7-UTG@+_`)'33_\`MI_Z+:@#VJBBLGQ!X@M/#NGFXN#OE;(AA!PTC?T`[GM]
M2`4!;U+4[+2+0W5_<+#"&"[B"22>P`Y)^GH:\F\2^.+_`%MGM[8M:V&X@(A(
M>12,?.0>1UX''/.<`UCZSKNH:]<B:_FW[,B.-1A8P3G`']3D\#).*S:8!111
M0`4444`%%%%`!1110`4444`%%%%`!1110!K>'_$%WX=U`7%N=\;8$T).%D7^
MA'8]OH2#[%X?\06GB+3Q<6YV2K@30DY:-OZ@]CW^H('@]:6A:S/H.K0W\(W[
M,J\98@2*>H./S'7D`X.*`/?**I:3JUIK6GQWME)OB;@@\,C=U8=B/_K]#5VD
M`4444`%%%%`!1110`4444`%%%%`!39)$AB>65U2-%+,S'`4#J2>PJ*\O+>PM
M);JZE6*")=SNW0#^I]N]>,^*O%5QXCN]J[HK")OW,)/)/]YO5OY=!W)`-3Q7
MX\GU3S]/TT^58-\K2X(>4=_HI].I`YZD5Q5%%,`HHHH`****`"BBB@`HHHH`
M****`"BBB@`IT<CPRI+$[)(C!E93@J1T(/8TVB@#T?PI\0?]1IVLM_LK>LWY
M!_U^;/IGN:]%CD2:))8G5XW4,K*<A@>A![BOG.NO\&^,GT.5;*]9GTUVX/4P
M$]QZKZC\1SD%`>OU\XU]#V=Y;W]I%=6LJRP2KN1UZ$?T/MVKYXH`****8!11
M10`5[7X"_P"1+T__`+:?^C&KQ2O:_`7_`")>G_\`;3_T8U`'1T444@"BBB@`
MHHHH`****`"BBB@`HHHH`****`/G&BBBF`4444`%%%%`'H_PI_YB_P#VQ_\`
M9Z]'KSCX4_\`,7_[8_\`L]>CT@"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444`>U^`O^1+T_P#[:?\`
MHQJZ.N<\!?\`(EZ?_P!M/_1C5T=(`HHHH`****`"BBH+R\M["TENKJ58H(EW
M.[=`/ZGV[T`<]XT\4?\`"/Z>L5J\9U"?A%/)C7G+X^O`SW]<$5XS6AK6KW&M
MZI-?7#-EV.Q"V1&F>%'3@?3GD]36?3`****`"BBB@`HHKNO#_P`.+F^07&KO
M)9Q'!6%0/,8$9R>NWDC@@GKP*`.'CC>:5(HD9Y'8*JJ,EB>@`[FMNU\&^(;R
M(R1:7,JAMN)2L1S]&(..>M>R:;I&GZ/`8=/M(X%/WBHRS<D\L>3U/4\5=I`>
M3?\`"L-;_P"?K3_^_C__`!%'_"L-;_Y^M/\`^_C_`/Q%>LT4`>17'PTUV&!I
M(WLYV&,1QRD,>>VX`?K63=^$/$%EL\W2KAM^<>2!+T]=F<=>]>YT4`?.-%>]
M:QX>TS78BM];*T@7"S+\LB]<8;T&2<'(SVKSCQ!\/+_35>XTYFOK?=_JU0^:
MH)/8?>`XY'KT`%,#C****`"BBB@`HHHH`]F\%^*/^$@T]HKIXQJ$'#J.#(O&
M'Q]>#COZ9`KJ*\!T75[C1-4AOK=FRC#>@;`D3/*GKP?IQP>HKWJWN(KNVBN(
M&W12H'1L$94C(.#[4@)****`"BBB@`HHHH`\V^*=X#+IUDLK;E5Y9(^<8.`I
M/8GAQ[<^M>=5VOQ/_P"1EMO^O-?_`$-ZXJF`4444`%%%%`!13HXWFE2*)&>1
MV"JJC)8GH`.YKI--\!:_J*AS;+:1E20UTVPD@XQM`+`_4?TH`YFBO4K#X7V$
M,N^^OIKE0P*I&@B!`ZAN22#QT(KI+7PIH%G$8XM)M64MNS*GFG/U;)QQTH`\
M)K0CT+5YHDEBTJ^>-U#*RV[D,#T(..17OD<:0Q)%$BI&BA551@*!T`'84ZD!
MX'_PCVM_]`?4/_`9_P#"FR:%J\,3RRZ5?)&BEF9K=P%`ZDG'`KWZB@#YQHKZ
M*N+>"[@:&XACFB;&Z.10RG!SR#[UA:EX(T#4E.;);:3:%$EK^[(`.>@^4GMD
M@_RI@>)45WFK?#*]MU:72[E;I=QQ#(`C@9&`#G!.,Y)V]/?%</<6\]I.T-Q#
M)#*N-T<BE6&1GD'VH`CHHHH`****`"BBB@#T/X;>(&2<Z%.<H^Z2W8DDAL9*
M8Z`8!;MSGKFO2Z^=;>XEM+F*XA;;+$X=&P#A@<@X/O7OND:E%K&DVVH0C"S)
MDKS\K=&7)`S@@C/?%("[1110`4444`%%%%`'SC1113`****`"ND\!?\`(Z:?
M_P!M/_1;5S=:GAW54T37(-1DC:585?"*<%B48`9[#)'/\Z`/9/$'B"T\.Z>;
MBX.^5LB&$'#2-_0#N>WU(!\4U;5KO6M0DO;V3?(W``X5%[*H[`?_`%^IHU;5
MKO6M0DO;V3?(W``X5%[*H[`?_7ZFJ5`!1110`4444`%%6;'3[O4[E;>RMY)Y
M3_"@S@9`R3V&2.3Q77Z;\,M3N5#W]S#9J5/R@>:X.>A`(&,<Y!/;\`#AZ*]?
MM?AOH%O*7E%U<J5QLEEP`?7Y0IS^/>KG_"!>&O\`H&_^1Y/_`(J@#Q2BO:)/
M`'AMXG1;!HV92`ZSOE3ZC)(S]0:Q[OX663[/L>I7$.,[_.19,^F,;<=_6@#R
M^BM_5O!FMZ0DDLUKYUNG6:`[UQC))'W@!@Y)`%8%`!1110`4444`%%%%`'5>
M!_$IT35!;7$C?8+E@K`L`L;D@!^>@['D<<\X`KV2OG&O9/`6O/K.B&*YD:2[
MM&"2,QR74_=8G'7@CN?ER>M(#JJ***`"BBB@`HHHH`****`"BBN*^(7B/^SM
M/_LJW;%U=I^\RF0L)R#SZDC'?C/3@T`<SXY\6/JMW)IME,ITZ)AN:,Y$[#N3
M_=!Z#H<9YXQQE%%,`HHHH`****`"BBB@`HKJ-)\`ZWJ3QM-!]BMVY,D_#`9P
M<)][/4C.`<=:ZRQ^&&FP[6O;RXN6#YP@$:E>/E(Y/KR".M`'E=%>VQ^!O#<4
MJ2+IBED8,`TKL,CU!;!'L:MW'A?0KF!H9-)LPK8R8XA&W7/#+@C\Z`/!Z*]F
MN/A]X<F@:..TD@8XQ)',Q8<]MQ(_2L+4OA:A4MI>H,&"C$=T,@G/)W*.!CMM
M/3WX`/-J*U-8\/:GH4I6^MF6,MA9E^:-NN,-ZG!.#@X[5ET`%%%%`!1110!T
M/A7Q5<>'+O:VZ6PE;]]"#R#_`'E]&_GT/8CGJ**`"BBB@`HHHH`*]K\!?\B7
MI_\`VT_]&-7BE>U^`O\`D2]/_P"VG_HQJ`.CHHHI`%%%%`!1110`4444`%%%
M%`!1110`4444`?.-%%%,`HHHH`****`/1_A3_P`Q?_MC_P"SUZ/7G'PI_P"8
MO_VQ_P#9Z]'I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110!\XT444P"BBB@`HHHH`]K\!?\B7I__;3_`-&-71USG@+_`)$O
M3_\`MI_Z,:NCI`%%%%`!1110`5Y[\3]6:."TTJ*3'FYFF49!*@X49Z$$[CCU
M4=*]"KP7Q'J0U;Q%?7J%3')(1&5!`*+\JG!YR0`:`,NBBBF`4444`%%%=U\.
M/#ZWUZVKW`S%:OMB4@$-)CJ?3:""..I'/%`&MX)\$_8_+U758O\`2>&@MV'^
MJ]&8?WO0=OKT[ZBBD`4444`%%%%`!1110`4444`<#XV\$_;/,U72HO\`2>6G
MMU'^M]64?WO4=_KU\OKZ.KR;XA>'/[.U#^U;=<6MV_[S+Y*S')/'H0,]^<].
M!0!Q5%%%,`HHHH`*]0^&>M>?93:/*?GM\RP\=4)^8=.S'/)R=WM7E];'A74G
MTKQ)93K*L<;2"*8NV%\MCAL\C@=>>,@'M0![M1112`****`"BBB@#RGXH1N/
M$%K*481M:A5;'!(=L@'U&1^8KAZ]9^)6DRWVC07L$<DCV;L7"XP(V'S,1U."
MJ].@R?IY-3`**='&\TJ11(SR.P5549+$]`!W-=YHOPSN9\2ZQ/\`9D_YXPD,
MYZ]6Y4=CQG(/:@#BK'3[O4[E;>RMY)Y3_"@S@9`R3V&2.3Q7;Z3\,+B1EDU:
MZ6*,J#Y5N=SY(/!8C`(..F[//UKT6QT^TTRV6WLK>."(?PH,9.`,D]S@#D\U
M9I`4--T/3-(4"PL886"E=X7+D$YP6/)&?4]A5^BB@`HHHH`****`"BBB@`HH
MHH`*Q_$'ANP\0VCQW$:I<;<1W*J-Z$9QSW7D\>_8\UL44`>#^(/#]WX=U`V]
MP-\;9,,P&%D7^A'<=OH03DU[MXE\/V_B'2WMY$7[0BEK>4G!1\>N#\IXR/Z@
M5X;<6\MI<RV\R[98G,;KD'#`X(R/>F!'1110`4444`%>D_"W4@8K[2V*A@PN
M(Q@Y(.%;)Z8&$_,]>WFU;_@J^^P>+;!RT@25_)8(?O;QM&?4;BI_"@#V^BBB
MD`4444`%%%%`'SC1113`****`"BBB@`HHHH`***GL[.XO[N*UM8FEGE;:B+U
M)_H/?M0!!7=>'_AQ<WR"XU=Y+.(X*PJ!YC`C.3UV\D<$$]>!72^%?`]OHB_:
M;\0W5^6RI`W)$`<C;D?>X!SCCH.Y/7T@*UCI]IIELMO96\<$0_A08R<`9)[G
M`')YJS110`4444`%%%%`!7'>*/`=MK&^ZT\1VU^S[G+$A)<]<@9P>^0.3G/7
M([&B@#YXO+.XL+N6UNHFBGB;:Z-U!_J/?O4%>S>-/"__``D&GK+:I&-0@Y1C
MP9%YRF?KR,]_3)->,TP"BBB@`HHHH`*Z;P+K#Z5XD@B^8P7C""11ZD_*<9`R
M#W]"U<S10!]'450T/4AJ^B6=^"I::,%]H(`<<,!GG`8$5?I`%%%%`!1110`4
M444`5M0OH-,T^>]N&Q%"A=N1D^PSW)X'N:\#U"^GU/4)[VX;,LSEVY.![#/8
M#@>PKOOB9KG^IT6!_26XVG_OE3@_\"((_NFO.*8!1110`4444`%%%7=)TF[U
MK4([*RCWR-R2>%1>[,>P'_UNIH`-)TF[UK4([*RCWR-R2>%1>[,>P'_UNIKU
MGPWX)T_18(IKB*.ZU`?,TS#*H<@X0'I@CAL9Z],X&EX?\/VGAW3Q;VXWRM@S
M3$8:1OZ`=AV^I).M2`****`"BBB@`HHHH`*XK7/AQI]]OGTU_L5P<GR\9B8\
MGIU7DCIP`/NUVM%`'SU?:?=Z9<M;WMO)!*/X7&,C)&0>XR#R.*K5[_JVBV&M
MVC6]]`KC:0D@`WQDXY4]CP/KCG(KQWQ'X5O_``Y*IGVS6TC$1SQ@X)YX8=FQ
MSC\B<&F!A4444`%%%%`!1110`4444`%>U^`O^1+T_P#[:?\`HQJ\4KVOP%_R
M)>G_`/;3_P!&-0!T=%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@#YQHHHI
M@%%%%`!1110!Z/\`"G_F+_\`;'_V>O1Z\X^%/_,7_P"V/_L]>CT@"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`^<:***8!1
M110`4444`>U^`O\`D2]/_P"VG_HQJZ.N<\!?\B7I_P#VT_\`1C5T=(`HHHH`
M****`,?Q7?OIOA?4+J+=Y@CV*5;:5+$*&!]1NS^%>$UZS\3KCR_#L$*S;6EN
M5S&&P74*Q/'<`[?QQ7DU,`HHHH`****`'1QO-*D42,\CL%55&2Q/0`=S7O\`
MI&FQ:/I-MI\)RL*8+<_,W5FP2<9))QVS7DWP_L?MOBV!RL;);(TS!QGH-HQ[
MAF4_A7LU(`HHHH`****`"BBB@`HHHH`****`"J&N::-7T2\L"%+31D)N)`#C
ME2<<X#`&K]%`'SC16[XRM4L_%^I11EBK2"4[CSEU#G\,L:PJ8!1110`4444`
M>_Z'>&_T&PNGE6626!&D=<8+X^;IP#G/':K]<G\.;O[3X2CBV;?LTSQ9SG=D
M[\^WW\?A764@"BBB@`HHHH`;)&DT3Q2HKQNI5E89#`]01W%<O=?#S0+F^%R(
MIH5W;FAB?$;'.3QC(!Z84CCIBNJHH`S=+T#2M&W'3[*.%FSE^68@XXW')QP.
M,XK2HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"O*_B9I+6^K0ZG'
M'^ZN4"2,,G]XOKV&5QCUVFO5*Y?X@6/VWPE.X61GMG690@ST.TY]@K,?PH`\
M9HHHI@%%%%`!4EO<2VES%<0MMEB<.C8!PP.0<'WJ.B@#Z,CD2:))8G5XW4,K
M*<A@>A![BG5E^&Y$E\,:6T;JZBUC4E3D9"@$?4$$?A6I2`****`"BBB@#YQH
MHHI@%%%%`!1110`445/9V=Q?W<5K:Q-+/*VU$7J3_0>_:@`L[.XO[N*UM8FE
MGE;:B+U)_H/?M7LWA7PK;^'+3<VV6_E7]],!P!_=7T7^?4]@#PKX5M_#EIN;
M;+?RK^^F`X`_NKZ+_/J>P'0T@"BBB@`HHHH`****`"BBB@`HHHH`*\F^(^A_
M8=674H8\6]Y]_:.%E'7H,#<.>N2=QKUFL?Q3I)UKP[=6<:J9]H>'*@G>O(`S
MC!/*Y_VC0!X31113`****`"BBB@#UGX9W_VCP_-9M+N>UF.U-N-J-R.<<Y;?
M[_I7:UY?\++O9J>H6>S/FPK+OSTV'&,>^_\`2O4*0!1110`4444`%-DD2&)Y
M975(T4LS,<!0.I)["G5R?Q#U/[#X9>W1\2WCB(8DVL%ZL<=Q@!3_`+WX$`\H
MU2_?5-4NKZ3<&GD9PK-N*@GA<^@&!^%5***8!1110`4444`%>T>#?#":!IJR
MSQ+_`&E,O[YMV[:,\(#V'3..I[D`5Q'P^\/MJ>K#49ABULG##(/SR=5`(]#@
MG\!CFO7:0!1110`4444`%%%%`!1110`4444`%07EG;W]I+:W42RP2KM=&Z$?
MT/OVJ>B@#Q+Q5X5N/#EWN7=+82M^YF(Y!_NMZ-_/J.X'/5]#WEG;W]I+:W42
MRP2KM=&Z$?T/OVKQGQ5X5N/#EWN7=+82M^YF(Y!_NMZ-_/J.X#`YZBBB@`HH
MHH`****`"O:_`7_(EZ?_`-M/_1C5XI7M?@+_`)$O3_\`MI_Z,:@#HZ***0!1
M110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"BBB@#T?X4_\`,7_[
M8_\`L]>CUYQ\*?\`F+_]L?\`V>O1Z0!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`?.-%%%,`HHHH`****`/:_`7_(EZ?_VT
M_P#1C5T=<YX"_P"1+T__`+:?^C&KHZ0!1110`4444`><?%;_`)A'_;;_`-DK
MSBNZ^*-Q*VN6=N6_=1VV]5P.&9B"<_15_*N%I@%%%%`!1110!Z+\*HT,NJRE
M%,BK$JMCD`[\@'T.!^0KTFN*^&'_`"+5S_U^-_Z`E=K2`****`"BBB@`HHHH
M`****`"BBB@`HHHH`\I^*$;CQ!:RE&$;6H56QP2';(!]1D?F*X>O1_BM_P`P
MC_MM_P"R5YQ3`****`"BBB@#U3X77$3:'>6X;]['<[V7!X5E`!S]5;\J[JO.
M/A3_`,Q?_MC_`.SUZ/2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`JMJ%I]OTRZL]^S[1"\6_&=NX$9QWZU9HH`^<:*GO+
M5[&^N+24J9()&B8J>"5.#CVXJ"F`4444`%%%%`'M?@+_`)$O3_\`MI_Z,:NC
MKF?`$B/X,LE1U9D:17`.2IWL<'T."#^(KIJ0!1110`4444`?.-%%%,`HHHH`
M****`'1QO-*D42,\CL%55&2Q/0`=S7M/A'PO!X?T]9)$SJ$R`SNV,IWV#'8'
M\R,^@&)\-_#\4-E_;<PCDEFRMOP<Q*"58_4D8^@Z\D5WU(`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`\'\3V/\`9WB;4+8+&JB8NBQC"JK?,H`[8!`K
M)KN/B?9F+7K:Z$2K'/!M+C&7=2<Y[Y`*<GV]*X>F`4444`%%%%`'4?#ZXEA\
M8VL<;869)$D&!RNTMC\U!_"O9J\)\*73V?BO3)8PI9IUB.X<8?Y#^.&->[4@
M"BBB@`HHHH`*\I^)NI"YUNWL$*E;2/+<$$.^"0>Q&T(>/4_AZM7@?B"__M3Q
M!?7@E\U))F\M]NW*#A>,#^$#WH`S:***8!1110`445M^$M,_M;Q-96[)NB5_
M-ES'O7:O.&'H2`O/][\*`/6/"FB_V%X?@M7&+A_WL_/\9ZCJ1P`!QP<9[UMT
M44@"BBB@`HHHH`****`"BBB@`HHHH`****`"H+RSM[^TEM;J)98)5VNC="/Z
M'W[5/10!X9XH\/R^'=6>WQ(UJ_S6\K@?.O<<=P3@].QP,BL2O?\`6M)M];TN
M:QN%7#J=CE<F-\<,.G(^O/(Z&O`*8!1110`4444`%>U^`O\`D2]/_P"VG_HQ
MJ\4KVOP%_P`B7I__`&T_]&-0!T=%%%(`HHHH`****`"BBB@`HHHH`****`"B
MBB@#YQHHHI@%%%%`!1110!Z/\*?^8O\`]L?_`&>O1Z\X^%/_`#%_^V/_`+/7
MH](`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`/G&BBBF`4444`%%%%`'M?@+_D2]/\`^VG_`*,:NCKG/`7_`")>G_\`;3_T
M8U='2`****`"BBB@#RGXH1N/$%K*481M:A5;'!(=L@'U&1^8KAZ]'^*W_,(_
M[;?^R5YQ3`****`"BBB@#UGX8?\`(M7/_7XW_H"5VM>;?"J1!+JL1=1(RQ,J
MYY(&_)`]!D?F*])I`%%%%`!1110`4444`%%%%`!1110`4444`>7_`!3N]^IZ
M?9[,>5"TN_/7><8Q[;/UK@:ZKXB73W'B^>)PH6WCCB3`Y(*[^??+G]*Y6F`4
M444`%%%%`'IGPKMY5MM3N"O[J1XXU;(Y90Q(Q]&7\Z]"KBOAA_R+5S_U^-_Z
M`E=K2`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`\#\0_\C+JO_7Y-_P"AFLVM+Q#_`,C+JO\`U^3?^AFLVF`4444`
M%%%%`'K/PP_Y%JY_Z_&_]`2NUKBOAA_R+5S_`-?C?^@)7:T@"BBB@`HHHH`^
M<:***8!1110`4444`>U^`O\`D2]/_P"VG_HQJZ.N<\!?\B7I_P#VT_\`1C5T
M=(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`\_\`BG:N]CIUV"OEQ2/$
MPSSE@",>WR']*\QKUGXG_P#(M6W_`%^+_P"@/7DU,`HHHH`****`-+P]_P`C
M+I7_`%^0_P#H8KWROGK3[O[!J=K>;-_V>9)=F<;MI!QGMTKZ%I`%%%%`!111
M0!4U6Z>QTB]NX@ID@@DE4,."54D9]N*^?*]K\>7'V?P=?8F\IY-D:X;:6RPR
MH]<KNR/3->*4P"BBB@`HHHH`*]'^%EA_R$-1>+^[!')N_P"!.,9_W.<?3O7G
M%>R?#NU2W\(02H6+7$DDKY/`(;9Q[80?K0!U5%%%(`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`*^<:^CJ^<:`"BBBF`4444`%>U^`O^1+T__MI_Z,:O
M%*]K\!?\B7I__;3_`-&-0!T=%%%(`HHHH`****`"BBB@`HHHH`****`"BBB@
M#YQHHHI@%%%%`!1110!Z/\*?^8O_`-L?_9Z]'KSCX4_\Q?\`[8_^SUZ/2`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#YQH
MHHI@%%%%`!1110![7X"_Y$O3_P#MI_Z,:NCKG/`7_(EZ?_VT_P#1C5T=(`HH
MHH`****`.*^)UOYGAV"98=S17*YD"Y**58'GL"=OXXKR:O>/$]C_`&CX9U"V
M"R,QA+HL8RS,OS*`.^2`*\'I@%%%%`!1110!TW@+4AIWBNW#E1'=*;=B0206
MP5QCN6"C\3]:]HKYSCD>&5)8G9)$8,K*<%2.A![&O>/#VL)KNB6]\NT2,NV9
M5_AD'WAC)P.XSS@BD!J4444`%%%%`!1110`4444`%%%%`!4=Q<16EM+<3MMB
MB0N[8)PH&2<#VJ2N*^(^N?8=)7387Q<7GW]IY6(=>AR-QXZ8(W"@#RV\NGOK
MZXNY0HDGD:5@HX!8Y./;FH***8!1110`445);V\MW<Q6\*[I97$:+D#+$X`R
M?>@#VOP3;RVW@[3HYEVL4:0#(/RLQ93QZ@@UOU';V\5I;16\"[8HD$:+DG"@
M8`R?:I*0!1110`4444`%%%%`!1110`4444`%%%%`!152ZU73K&417=_:V\A7
M<%EF5"1ZX)Z<&L"Z^(GAZWB#Q7$URQ;&R*%@0/7YMHQ^/>@#JJ*\_NOBG:I*
M!::7-+'MY:641G/I@!N.G.:S;KXI:B\H-II]K%'MY64M(<^N05XZ<8H`]2HK
MR23XFZX\3HL-C&S*0'6-LJ?498C/U!JA_P`)[XE_Z"7_`)`C_P#B:`/:J*\5
M_P"$]\2_]!+_`,@1_P#Q-'_">^)?^@E_Y`C_`/B:`/:J*\5_X3WQ+_T$O_($
M?_Q-'_">^)?^@E_Y`C_^)H`]JHKQ7_A/?$O_`$$O_($?_P`31_PGOB7_`*"7
M_D"/_P")H`S?$/\`R,NJ_P#7Y-_Z&:S:DN+B6[N9;B9MTLKEW;`&6)R3@>]1
MTP"BBB@`HHHH`]9^&'_(M7/_`%^-_P"@)7:UQ7PP_P"1:N?^OQO_`$!*[6D`
M4444`%%%%`'SC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/
M_P"VG_HQJZ.D`4444`%%%%`!1110`4444`%%%%`!1110`4444`<G\1K3[3X2
MDEW[?LTR2XQG=D[,>WW\_A7CM>U^/?\`D2]0_P"V?_HQ:\4I@%%%%`!1110`
M5]'5\XU]'4@"BBB@`HHHH`XCXH2(/#]K$742-=!E7/)`1LD#T&1^8KRBO1_B
MM_S"/^VW_LE><4P"BBB@`HHHH`*]_P!"C>'P_IL4J,DB6L2LK#!4A!D$=C7@
M%?1U(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"OG&OHZOG&@`
MHHHI@%%%%`!7M?@+_D2]/_[:?^C&KQ2O:_`7_(EZ?_VT_P#1C4`='1112`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444`>C_"G_F+_P#;
M'_V>O1Z\X^%/_,7_`.V/_L]>CT@"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444`>U^`O^1+T_\`[:?^
MC&KHZYSP%_R)>G_]M/\`T8U='2`****`"BBB@`KPSQ7HO]A>()[5!BW?][!S
M_`>@ZD\$$<\G&>]>YUQWQ!\/KJ>DG481BZLD+'`'SQ]6!)]!DC\1CF@#R*BB
MBF`4444`%=1X+\4?\(_J#173R'3Y^'4<B-N,/CZ<'';UP!7+T4`?1D<B31)+
M$ZO&ZAE93D,#T(/<4ZO(/!OC)]#E6RO69]-=N#U,!/<>J^H_$<Y!]8L[RWO[
M2*ZM95E@E7<CKT(_H?;M2`GHHHH`****`"BBB@`HHK-UG7=/T&V$U_-LWY$<
M:C+2$#.`/ZG`Y&2,T`2ZMJUIHNGR7M[)LB7@`<L[=E4=R?\`Z_05X=K6KW&M
MZI-?7#-EV.Q"V1&F>%'3@?3GD]34WB#Q!=^(M0-Q<'9&N1#"#E8U_J3W/?Z`
M`9-,`HHHH`****`"NL^'FF?;O$R7#IF*S0RG,>Y2W11GL<DL/]W\1R=>U^"=
M#_L7P_'YL>V[N<2S9&"N?NJ>`>!V/0EJ`.CHHHI`%%%%`!1110`4444`%%%8
M'B#Q=IOA]"DC^?=G(%O$PW`XR-W]T<CWYX!H`WZPM6\7Z+HZL)KM9IE8J8+<
MAW!!`(/.%(SW(Z&O,M<\;:OK6^+S?LMHV1Y,)QN'/#-U;@X(X!QTKFZ`.^U/
MXGW<NZ/3+..!?F`EF.]L?PL`,`'O@[A_7E[[Q/K>H[A<ZG<%638R(WEJR\Y!
M5<`]>XK)HI@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`>
ML_##_D6KG_K\;_T!*[6N*^&'_(M7/_7XW_H"5VM(`HHHH`****`/G&BBBF`4
M444`%%%%`'M?@+_D2]/_`.VG_HQJZ.N<\!?\B7I__;3_`-&-71T@"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@#G/'O\`R)>H?]L__1BUXI7M?CW_`)$O
M4/\`MG_Z,6O%*8!1110`4444`%?1U?.-?1U(`HHHH`****`/+?BE=.^KV-H0
MOEQ0&53CG+,0<^WR#]:X.NU^)_\`R,MM_P!>:_\`H;UQ5,`HHHH`****`-+P
M]_R,NE?]?D/_`*&*]\KP/P]_R,NE?]?D/_H8KWRD`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_R)>G_P#;
M3_T8U>*5[7X"_P"1+T__`+:?^C&H`Z.BBBD`4444`%%%%`!1110`4444`%%%
M%`!1110!\XT444P"BBB@`HHHH`]'^%/_`#%_^V/_`+/7H]><?"G_`)B__;'_
M`-GKT>D`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`'SC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"V
MG_HQJZ.D`4444`%%%%`!1110!XOXR\,/H&I-+!$W]FS-^Y;=NVG'*$]CUQGJ
M.Y(-<S7JGQ#U_3XM/?2##'=7DF&P>EOZ-D?Q8Z#T//!P?*Z8!1110`4444`%
M7=-U?4-'G,VGW<D#'[P4Y5N".5/!ZGJ.*I44`>DZ;\4D*A=4T]@P4YDM3D$Y
MX&UCP,=]QZ>_'56GB_P_>[_*U6W79C/G$Q=?3?C/3M7AE%`'T5;W$%W`LUO-
M'-$V=LD;!E.#C@CWJ2OG&BD!]#W5Y:V,0EN[F&WC+;0TL@0$^F3WX-8]]XU\
M/V&X/J,<SA-X6W!DW=>,CY0>.Y%>(44P/0-6^)]Q(S1Z3:K%&5(\VX&Y\D#D
M*#@$'/7=GCZ5P=Q<3W<[37$TDTK8W22,68X&.2?:HZ*`"BBB@`HHHH`***NZ
M3I-WK6H1V5E'OD;DD\*B]V8]@/\`ZW4T`;O@?PV=;U07-Q&WV"V8,Q*@K(X(
M(3GJ.YX/''&0:]DJEI.DVFBZ?'964>R)>23RSMW9CW)_^MT%7:0!1110`444
M4`%%%%`!39)$AB>65U2-%+,S'`4#J2>PHDD2&)Y975(T4LS,<!0.I)["O(O&
M7C)]<E:RLF9--1N3T,Y'<^B^@_$\X``-3Q1\0VEWV>AOB)DP]V5*MD_W,XQQ
MD9(SSQC`)\\HHI@%%%%`!1110`4444`%%%%`!16A'H6KS1)+%I5\\;J&5EMW
M(8'H0<<BK=IX0\07N_RM*N%V8SYP$77TWXST[4`8E%=)_P`(%XE_Z!O_`)'C
M_P#BJ/\`A`O$O_0-_P#(\?\`\50!S=%=)_P@7B7_`*!O_D>/_P"*H_X0+Q+_
M`-`W_P`CQ_\`Q5`'-T5TG_"!>)?^@;_Y'C_^*H_X0+Q+_P!`W_R/'_\`%4`<
MW14EQ;RVES+;S+MEB<QNN0<,#@C(]ZCH`****`"BBB@#UGX8?\BU<_\`7XW_
M`*`E=K7%?##_`)%JY_Z_&_\`0$KM:0!1110`4444`?.-%%%,`HHHH`****`/
M:_`7_(EZ?_VT_P#1C5T=<YX"_P"1+T__`+:?^C&KHZ0!1110`4444`%%%%`!
M1110`4444`%%%%`!1110!SGCW_D2]0_[9_\`HQ:\4KVOQ[_R)>H?]L__`$8M
M>*4P"BBB@`HHHH`*^CJ^<:^CJ0!1110`4444`>3?$_\`Y&6V_P"O-?\`T-ZX
MJNU^)_\`R,MM_P!>:_\`H;UQ5,`HHHH`****`-+P]_R,NE?]?D/_`*&*]\KP
M/P]_R,NE?]?D/_H8KWRD`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!7SC7T=7SC0`4444P"BBB@`KVOP%_R)>G_P#;3_T8U>*5[7X"_P"1+T__
M`+:?^C&H`Z.BBBD`4444`%%%%`!1110`4444`%%%%`!1110!\XT444P"BBB@
M`HHHH`]'^%/_`#%_^V/_`+/7H]><?"G_`)B__;'_`-GKT>D`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"
MBBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"VG_HQJZ.D`4444`%%%%`!
M6%XJ\1IX<TOSPBR7,K;((R<`G'+$==H[X]0.,YK;DD2&)Y975(T4LS,<!0.I
M)["O"?$FMRZ_K,MX_$8^2!=H!6,$X!Z\\DGGJ?3%`&;<7$MW<RW$S;I97+NV
M`,L3DG`]ZCHHI@%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`445
MU'AOP3J&M3Q37$4EKIY^9IF&&<8!P@/7(/#8QUZXP0#$TG2;O6M0CLK*/?(W
M))X5%[LQ[`?_`%NIKVOP_P"'[3P[IXM[<;Y6P9IB,-(W]`.P[?4DFSI.DVFB
MZ?'964>R)>23RSMW9CW)_P#K=!5VD`4444`%%%%`!1110`445E^(=830M$N+
MYMID5=L*M_%(?NC&1D=SCG`-`''?$3Q.\3'1+*5D8K_I;!<'!`(0'T(.3]0,
M]17FU.DD>:5Y979Y'8LS,<EB>I)[FFTP"BBB@`HHHH`**='&\TJ11(SR.P55
M49+$]`!W->C^&_APGE?:->5O,W';:I)P!R,LR]3W`![<YS@`'#:;H>IZNP%A
M8S3*6*[PN$!`S@L>`<>I[BNUTWX6N6#:IJ"A0QS':C)(QP=S#@Y[;3T]^/1X
MXTAB2*)%2-%"JJC`4#H`.PIU(#`L?!7A^PVE-.CF<)L+7!,F[IS@_*#QV`K;
MM[>"T@6&WACAB7.V.-0JC)SP![U)10`4444`%%%%`!1110`4444`>!^(?^1E
MU7_K\F_]#-9M:7B'_D9=5_Z_)O\`T,UFTP"BBB@`HHHH`]9^&'_(M7/_`%^-
M_P"@)7:UQ7PP_P"1:N?^OQO_`$!*[6D`4444`%%%%`'SC1113`****`"BBB@
M#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"VG_HQJZ.D`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`<YX]_Y$O4/^V?_`*,6O%*]K\>_\B7J'_;/_P!&
M+7BE,`HHHH`****`"OHZOG&OHZD`4444`%%%%`'E?Q1MY5URSN"O[J2V\M6R
M.65B2,?1E_.N%KT?XK?\PC_MM_[)7G%,`HHHH`****`)+>XEM+F*XA;;+$X=
M&P#A@<@X/O7T57SC7T+I]W]OTRUO-FS[1"DNS.=NX`XSWZT@+-%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`5\XU]'5\XT`%%%%,`HHHH`*]K\!?
M\B7I_P#VT_\`1C5XI7M?@+_D2]/_`.VG_HQJ`.CHHHI`%%%%`!1110`4444`
M%%%%`!1110`4444`?.-%%%,`HHHH`****`/1_A3_`,Q?_MC_`.SUZ/7G'PI_
MYB__`&Q_]GKT>D`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`'SC1113`****`"BBB@#VOP%_P`B7I__`&T_]&-71USG@+_D
M2]/_`.VG_HQJZ.D`4444`%%%%`'`_$S6O(LH='B/SW&)9N.B`_*.G=AG@Y&W
MWKR^M;Q+JS:SX@N[OS-\6\I#C(`C'"X!Z9')]R:R:8!1110`445UGP^T7^U/
M$`NI!FWL<2GGJ_\``.H/4$]Q\N#UH`Z_P=X,M]/TTW.HPK/<W<8WPRIE8TR&
M"E3U;(!.1P1@=,G+USX9_?GT6?U/V:8_4X5OR`!_%J]'HI`?/5]I]WIERUO>
MV\D$H_A<8R,D9![C(/(XJM7T5<6\%W`T-Q#'-$V-T<BAE.#GD'WKF;_X>:!>
MR^8D4UHQ8LPMWP&)]F!``[`8ZTP/&Z*[Z[^%EZFS['J5O-G._P`Y&CQZ8QNS
MW]*QY/`'B1)71;!9%5B`ZSIAAZC)!Q]0*`.9HK6N/"^NVT[0R:3>%EQDQQ&1
M>F>&7(/YU'_PCVM_]`?4/_`9_P#"@#-HK6M_"^NW,ZPQZ3>!FS@R1&->F>6;
M`'YU>_X0+Q+_`-`W_P`CQ_\`Q5`'-T5W5O\`"[5&G47%]9QQ<[FCW.PX[`@9
MY]ZVK'X8:;#M:]O+BY8/G"`1J5X^4CD^O((ZT`>5UOZ3X,UO5TCEAM?)MWZ3
M3G8N,9!`^\0<C!`(KUO3?#FCZ2P>RT^&.0,6$A&]P2,'#-D@8[9]?6M2D!R>
MB_#[2-+Q)=+]ON!_%,OR#KT3D=".N>1D8KK***`"BBB@`HHHH`****`"BBB@
M`KROXF:LUQJT.F1R?NK9`\BC(_>-Z]CA<8]-QKU2OG[6+[^T]9O+T-(5FF9T
M\P_,%S\H/T&!^%`%*BBBF`4444`%%%=1X#T2+6/$`-S%YEK;(975D)5FZ*I/
MUYP>NTC'6@#L_`WA--*M(]2O86&HRJ=JR#!@4]@/[Q'4]1G''.>SHHI`%%%%
M`!1110`4444`%%%%`!1110`4444`>!^(?^1EU7_K\F_]#-9M:7B'_D9=5_Z_
M)O\`T,UFTP"BBB@`HHHH`]9^&'_(M7/_`%^-_P"@)7:UQ7PP_P"1:N?^OQO_
M`$!*[6D`4444`%%%%`'SC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>
M`O\`D2]/_P"VG_HQJZ.D`4444`%%%%`!1110`4444`%%%%`!1110`4444`<Y
MX]_Y$O4/^V?_`*,6O%*]K\>_\B7J'_;/_P!&+7BE,`HHHH`****`"OHZOG&O
MHZD`4444`%%%%`'"_%&WB;0[.X*_O8[GRU;)X5E)(Q]57\J\KKV;X@V\4W@Z
MZDD7+0O')&<GAMP7/Y,1^->,TP"BBB@`HHHH`*]S\(7?VWPEILNS9MA$6,Y^
MX2F?QVY_&O#*];^&=X9_#<EN\JLUO.RJG&40@,,]\%B_)]_2@#LZ***0!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`5\XU]'5\XT`%%%%,`HHHH`*]K\
M!?\`(EZ?_P!M/_1C5XI7M?@+_D2]/_[:?^C&H`Z.BBBD`4444`%%%%`!1110
M`4444`%%%%`!1110!\XT444P"BBB@`HHHH`]'^%/_,7_`.V/_L]>CUYQ\*?^
M8O\`]L?_`&>O1Z0!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`?.-%%%,`HHHH`****`/:_`7_(EZ?\`]M/_`$8U='7.>`O^
M1+T__MI_Z,:NCI`%%%%`!5#7+PV&@W]TDJQ210.T;MC`?'R]>"<XX[U?KG/'
MO_(EZA_VS_\`1BT`>*4444P"BBB@`KUOX9V9@\-R7#Q*K7$[,K\9=``HSWP&
M#\'W]:\DKVCP!(C^#+)4=69&D5P#DJ=['!]#@@_B*`.FHHHI`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110!0UV1X?#^I2Q.
MR2):RLK*<%2$."#V->`5[7X]_P"1+U#_`+9_^C%KQ2F`4444`%%%%`!7KOPV
ML?LWADW++'NNIF<,H^;:OR@$^Q#'\?>O(J]V\*6J6?A33(HRQ5H%E.X\Y?YS
M^&6-`&Q1112`****`"BBB@`HHHH`****`"BBB@`HHHH`\#\0_P#(RZK_`-?D
MW_H9K-K2\0_\C+JO_7Y-_P"AFLVF`4444`%%%%`'K/PP_P"1:N?^OQO_`$!*
M[6N*^&'_`"+5S_U^-_Z`E=K2`****`"BBB@#YQHHHI@%%%%`!1110![7X"_Y
M$O3_`/MI_P"C&KHZYSP%_P`B7I__`&T_]&-71T@"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@#G/'O_(EZA_VS_\`1BUXI7M?CW_D2]0_[9_^C%KQ2F`4
M444`%%%%`!7T=7SC7T=2`****`"BBB@"EK-O+=Z'J%O"NZ66VDC1<@98J0!D
M^]?/U?1U?/VL6/\`9FLWED%D"PS,B>8/F*Y^4GZC!_&@"E1113`****`"NZ^
M&%]Y.LW=DS1JMQ"'&XX8LAX`_!F/X>U<+6AH>I'2-;L[\%@L,@+[0"2AX8#/
M&2I(H`]^HIL<B31)+$ZO&ZAE93D,#T(/<4ZD`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`07EY;V%I+=74JQ01+N=VZ`?U/MWKYXKL?&WBZ75[F33K1]
MNGQ.0Q5@?/8'[V1_#GH/Q],<=3`****`"BBB@`KVOP%_R)>G_P#;3_T8U>*5
M[7X"_P"1+T__`+:?^C&H`Z.BBBD`4444`%%%%`!1110`4444`%%%%`!1110!
M\XT444P"BBB@`HHHH`]'^%/_`#%_^V/_`+/7H]><?"G_`)B__;'_`-GKT>D`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'S
MC1113`****`"BBB@#VOP%_R)>G_]M/\`T8U='7.>`O\`D2]/_P"VG_HQJZ.D
M`4444`%<=\2_/_X19/*\S9]I3S=F<;<-][VW;>O?%=C7/>.8WE\&:BL:,[!4
M8A1DX#J2?H`"?PH`\2HHHI@%%%%`!7>?#;7DL[N72;F14BN6#P%C@>9P"O3J
MPQU/\.!R:X.B@#Z.HKS;PQ\1!%%%9:V6*HI`O.6.!T#@#)/4;A[9'4UZ%:WE
MK?1&6TN8;B,-M+12!P#Z9'?D4@)Z***`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@#G/'O\`R)>H?]L__1BUXI7M_C:WEN?!VHQP
MKN8(LA&0/E5@S'GT`)KQ"F`4444`%%%%`!7O'A>XBN?"VER0MN46R(3@CYE&
MUASZ$$5X/7LGP[NDN/"$$2!@UO))$^1P26W\>V''ZT`=51112`****`"BBB@
M`HHHH`****`"BBB@`ILDB0Q/+*ZI&BEF9C@*!U)/84ZO*_'GBZ+4\Z5I[[K6
M-P99E8XE8?PCU4'G/<@8Z9(!R6LW$5WKFH7$#;HI;F1T;!&5+$@X/M5*BBF`
M4444`%%%%`'K/PP_Y%JY_P"OQO\`T!*[6N*^&'_(M7/_`%^-_P"@)7:T@"BB
MB@`HHHH`^<:***8!1110`4444`>U^`O^1+T__MI_Z,:NCKG/`7_(EZ?_`-M/
M_1C5T=(`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`YSQ[_R)>H?]L_\`
MT8M>*5[7X]_Y$O4/^V?_`*,6O%*8!1110`4444`%?1U?.-?1U(`HHHH`****
M`"O(OB38_9O$PN563;=0JY9A\NY?E(!]@%/X^]>NUQGQ*TT77AU+T!?,LY`2
M23G8V%(`Z$YV'GT/X@'DE%%%,`HHHH`****`/8OA]K7]J>'Q:R'-Q8XB/'5/
MX#T`Z`CN?ER>M=97AGA36O["\0073G%N_P"ZGX_@/4]">"`>.3C'>O<8Y$FB
M26)U>-U#*RG(8'H0>XI`.HHHH`****`"BBB@`HHHH`****`"BBB@`KS'QUXR
M>:6?1=.9DB1C'<R]"Y'!0>B]B>_3IUT/&WC;['YFE:5+_I/*SW"G_5>JJ?[W
MJ>WUZ>7T`%%%%,`HHHH`****`"O:_`7_`")>G_\`;3_T8U>*5[7X"_Y$O3_^
MVG_HQJ`.CHHHI`%%%%`!1110`4444`%%%%`!1110`4444`?.-%%%,`HHHH`*
M***`/1_A3_S%_P#MC_[/7H]><?"G_F+_`/;'_P!GKT>D`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"BBB
M@#VOP%_R)>G_`/;3_P!&-71USG@+_D2]/_[:?^C&KHZ0!1110`5!>6J7UC<6
MDI81SQM$Q4\@,,''OS4]%`'SQ>6KV-]<6DI4R02-$Q4\$J<''MQ4%>A_$GP^
MR3C78!E'VQW"@$D-C`?/0#`"]N<=<UYY3`****`"BBB@`J2WN)[2=9K>:2&5
M<[9(V*L,C'!'M4=%`&_;^-O$=M`L,>J2%5S@R(LC=<\LP)/YUK?\+/UO_GUT
M_P#[]O\`_%UQ5%`'H=O\5)U@47&DQR2\[FCG**>>P(../>I/^%K?]07_`,FO
M_L*\XHH`]'_X6M_U!?\`R:_^PJ[;_%'2V@4W%C>1R\[ECVNHY[$D9X]J\KHH
M`]9_X6?HO_/KJ'_?M/\`XNC_`(6?HO\`SZZA_P!^T_\`BZ\FHH`]FM_B#X<F
M@622[D@8YS')"Q8<]]H(_6I?^$]\-?\`02_\@2?_`!->*44`>U_\)[X:_P"@
ME_Y`D_\`B:OQ^)-#EB21=7L0KJ&`:=5.#Z@G(/L:\%HH`^A[6\M;Z(RVES#<
M1AMI:*0.`?3([\BIZ^<:T+/7-5L%B2UU&ZBCB;<D:RG8#G/W>A&>V.:0'OU%
M>16/Q)UNVVK<BWNUWY8NFQMO&5!7`'U(/7O75:;\2M'NE`O4FLI-I))7S$SG
M@`KR3CG[H[_B`=G14=O<07<"S6\T<T39VR1L&4X.."/>I*`"BBB@`HHHH`J:
MK:O?:1>VD1423P21*6/`+*0,^W-?/E?1U>!^(+#^R_$%]9B+RDCF;RTW;L(>
M5YR?X2/>@#-HHHI@%%%%`!79_#C6$L-;DL9MJQWRA58\8D7.T9)Z')'<D[:X
MRG1R/#*DL3LDB,&5E."I'0@]C0!]&45@>%/$T7B33V<IY5W!@3Q@';DYPRGT
M.#QU&/H3OT@"BBB@`HHHH`****`"BBB@`ILDB0Q/+*ZI&BEF9C@*!U)/856U
M+4[+2+0W5_<+#"&"[B"22>P`Y)^GH:\D\4>-+OQ!OM8E^SZ>'RL8^](!TWG/
MKS@<?7`-`&AXL\>OJD4NG:8&BM"Q5Y\X:9?0#^%3S[D8Z<BN'HHI@%%%%`!1
M110`4444`>L_##_D6KG_`*_&_P#0$KM:XKX8?\BU<_\`7XW_`*`E=K2`****
M`"BBB@#YQHHHI@%%%%`!1110![7X"_Y$O3_^VG_HQJZ.N<\!?\B7I_\`VT_]
M&-71T@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@#G/'O_(EZA_VS_P#1
MBUXI7M?CW_D2]0_[9_\`HQ:\4I@%%%%`!1110`5]'5\XU]'4@"BBB@`HHHH`
M*@O+5+ZQN+24L(YXVB8J>0&&#CWYJ>B@#YXO+5[&^N+24J9()&B8J>"5.#CV
MXJ"N^^)FB^1>PZQ$/DN,13<]'`^4]>ZC'`P-OO7`TP"BBB@`HHHH`*])^'_B
MQ/*31=0F;S-V+61SP1VCSV/IGUQQ@`^;44`?1U%<1X3\>IJDL6G:F%BNRH5)
M\X69O0C^%CQ[$YZ<"NWI`%%%%`!1110`4444`%%%4-6UJPT2T:XOIU0;24C!
M&^0C'"CN>1],\X%`%V21(8GEE=4C12S,QP%`ZDGL*\Q\;>-OMGF:5I4O^C<K
M/<*?];ZJI_N^I[_3KD^*/&EWX@WVL2_9]/#Y6,?>D`Z;SGUYP./K@&N7I@%%
M%%`!1110`4444`%%%%`!7M?@+_D2]/\`^VG_`*,:O%*]K\!?\B7I_P#VT_\`
M1C4`='1112`****`"BBB@`HHHH`****`"BBB@`HHHH`^<:***8!1110`4444
M`:6DZ]J>A^=_9USY/G;?,_=JV<9Q]X'U-:7_``GOB7_H)?\`D"/_`.)KFZ*`
M.D_X3WQ+_P!!+_R!'_\`$T?\)[XE_P"@E_Y`C_\`B:YNB@#I/^$]\2_]!+_R
M!'_\31_PGOB7_H)?^0(__B:YNB@#I/\`A/?$O_02_P#($?\`\31_PGOB7_H)
M?^0(_P#XFN;HH`Z3_A/?$O\`T$O_`"!'_P#$T?\`">^)?^@E_P"0(_\`XFN;
MHH`Z3_A/?$O_`$$O_($?_P`31_PGOB7_`*"7_D"/_P")KFZ*`.D_X3WQ+_T$
MO_($?_Q-'_">^)?^@E_Y`C_^)KFZ*`.D_P"$]\2_]!+_`,@1_P#Q-'_">^)?
M^@E_Y`C_`/B:YNB@#I/^$]\2_P#02_\`($?_`,31_P`)[XE_Z"7_`)`C_P#B
M:YNB@#V3P?XP'B-9+:YB6*_B4N1&#L=,XR,YP1D`@GW'<#JJ\'\+W$MMXITN
M2%MK&Y1"<`_*QVL.?4$BO>*0!1110`4444`?.-%%%,`HHHH`****`/:_`7_(
MEZ?_`-M/_1C5T=<YX"_Y$O3_`/MI_P"C&KHZ0!1110`4444`1W%O%=VTMO.N
MZ*5#&ZY(RI&",CVKQ;Q5X5N/#EWN7=+82M^YF(Y!_NMZ-_/J.X'MM-DC2:)X
MI45XW4JRL,A@>H([B@#YSHKT/Q!\-I4<SZ$?,0Y+6TK@,#G^%CP1@]SGCJ<U
MY])&\,KQ2HR2(Q5E88*D=01V-,!M%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`%FQU"[TRY6XLKB2"4?Q(<9&0<$=QD#@\5Z!X?^)0
M=DM]<14&W_CZC4XR`/O(,\GGD>HX`YKS:B@#Z*M[B"[@6:WFCFB;.V2-@RG!
MQP1[U)7AGA_Q1J'AV<?9WWVK.&EMV^Z_&.#_``G'<>@SG&*]FTG5K36M/CO;
M*3?$W!!X9&[JP[$?_7Z&D!=HHHH`*\T^)^DK'/::K%'CS<PS,,`%@,J<=22-
MPSZ*.E>EU2U?38M8TFYT^8X69,!N?E;JK8!&<$`X[XH`^?J*GO+.XL+N6UNH
MFBGB;:Z-U!_J/?O4%,`HHHH`****`+-CJ%WIERMQ97$D$H_B0XR,@X([C('!
MXKUOPUXXL-;5+>Y*VM_M`*.0$D8G'R$GD].#SSQG!->-T4`?1U%>(:3XSUO2
M$CBANO.MTZ0SC>N,8`!^\`,#`!`KK;'XIP-M74--D3"<O;N&W-Q_"<8'7N?Q
MZT@/0J*Y"U^)&@7$I24W5LH7.^6+()]/E+'/X=JN?\)[X:_Z"7_D"3_XF@#H
MZ*XK_A9^B_\`/KJ'_?M/_BZQ+OXIWK[/L>FV\.,[_.=I,^F,;<=_6@#TZ21(
M8GEE=4C12S,QP%`ZDGL*XS7/B/I]COATU/MMP,CS.D2GD=>K<@=."#]ZO.-4
MU_5=9VC4+V295QA.%4$9YVC`SR><9K-I@7=2U?4-8G$VH7<D[#[H8X5>`.%'
M`Z#H.:I444`%%%%`!13HXWE8K&C.P4L0HR<`9)^@`)_"FT`%%%%`!1110!ZS
M\,/^1:N?^OQO_0$KM:XKX8?\BU<_]?C?^@)7:T@"BBB@`HHHH`^<:***8!11
M10`4444`>U^`O^1+T_\`[:?^C&KHZYSP%_R)>G_]M/\`T8U='2`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`.<\>_P#(EZA_VS_]&+7BE>U^/?\`D2]0
M_P"V?_HQ:\4I@%%%%`!1110`5]'5\XU]'4@"BBB@`HHHH`****`*6KZ;%K&D
MW.GS'"S)@-S\K=5;`(S@@''?%>#ZA8SZ9J$]E<+B6%RC<'!]QGL1R/8U]"UP
M?Q$\-BZM#K-K&HG@7_2`JG=(G`#<=U_EW^4"@#RVBBBF`4444`%%%%`!79^'
M_B'?Z:J6^HJU];[O]8SGS5!([G[P'/!]>H`KC**`/=M)\4Z/K3+'9WB^>5!\
MF0;'S@G`!^\1@YQFMBOG&M"SUS5;!8DM=1NHHXFW)&LIV`YS]WH1GMCFD![]
M17BO_">^)?\`H)?^0(__`(FC_A/?$O\`T$O_`"!'_P#$T`>U50U+7-,TA2;^
M]AA8*&V%LN03C(4<D9]!V->*7GB36K]I3<:G=,LJ[719"J$8QC:,#&/;FLN@
M#T?7/B9]^#18/4?:9A]1E5_(@G\5K@;[4+O4[EKB]N))Y3_$YS@9)P!V&2>!
MQ5:BF`4444`%%%%`!3A&YB:4(QC5@K-C@$YP"?4X/Y&M3P_X?N_$6H"WMQLC
M7!FF(RL:_P!2>P[_`$!([;QUI-IHO@JSLK*/9$MXI)/+.VQ\LQ[D_P#UN@H`
M\SHHHH`****`"O:_`7_(EZ?_`-M/_1C5XI7M?@+_`)$O3_\`MI_Z,:@#HZ**
M*0!1110`4444`%%%%`!1110`4444`%%%%`'SC1113`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`KZ.KYQKZ.I`%%%%`!11
M10!\XT444P"BBB@`HHHH`]K\!?\`(EZ?_P!M/_1C5T=<YX"_Y$O3_P#MI_Z,
M:NCI`%%%%`!1110`445Y?XV\;?;/,TK2I?\`1N5GN%/^M]54_P!WU/?Z=0"?
MQ9\0'\V73]%D7R]I22['4G_IF>PZC=[\8P"?.J**8!1110`444Z.-YI4BB1G
MD=@JJHR6)Z`#N:`&T5WUC\+KN:V62]U".VE//E)'YF!@=3D<YR.,CCK5G_A5
M/_4:_P#)7_[.@#SBBO1_^%4_]1K_`,E?_LZ/^%4_]1K_`,E?_LZ`/.**[7_A
M6&M_\_6G_P#?Q_\`XBC_`(5AK?\`S]:?_P!_'_\`B*`.*HKM?^%8:W_S]:?_
M`-_'_P#B*ANOAOK]O$'B%K<L6QLBEP0/7Y@HQ^/>@#D**Z3_`(0+Q+_T#?\`
MR/'_`/%4?\(%XE_Z!O\`Y'C_`/BJ`.;HK6N/"^NVT[0R:3>%EQDQQ&1>F>&7
M(/YUDT`%%%%`!1110`4444`%:WA_Q!=^'=0%Q;G?&V!-"3A9%_H1V/;Z$@Y-
M%`'T'IFI6^KZ;!?VI8PS+E=PP00<$'W!!%6Z\B^'WB!M,U8:=,<VMZX49)^2
M3HI`'J<`_@<\5Z[2`****`.%^(/A?[=;'5[-(UN+="UP.AD0#KGIE0#[D=^`
M*\KKZ.KR_P`;>"?L?F:KI47^C<M/;J/]5ZLH_N^H[?3H`<#1113`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"I[.SN+^[BM;6)I9Y6VHB]2?Z#W[5;T
M;0M0UZY,%A#OV8,DC'"Q@G&2?Z#)X.`<5[#X?\+Z?X=@'V=-]TR!9;AOO/SG
M@?PC/8>@SG&:`,>V\*V_ASP?JK-MEOY;*7SI@.`-A^5?1?Y]3V`\DKWSQ#_R
M+6J_]><W_H!KP.@`HHHH`****`/6?AA_R+5S_P!?C?\`H"5VM<5\,/\`D6KG
M_K\;_P!`2NUI`%%%%`!1110!\XT444P"BBB@`HHHH`]K\!?\B7I__;3_`-&-
M71USG@+_`)$O3_\`MI_Z,:NCI`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`'.>/?^1+U#_MG_P"C%KQ2O:_'O_(EZA_VS_\`1BUXI3`****`"BBB@`KZ
M.KYQKZ.I`%%%%`!1110`4444`%%%%`'DGCGPF^E7<FI64*C3I6&Y8Q@0,>Q'
M]TGH>@SCCC/&5]&21I-$\4J*\;J596&0P/4$=Q7DGB[P3/I$[7>G123:>V6*
MJ"S08&2#_LX_B_`^I8''4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!70^%?"MQXCN]S;HK")OWTP')/]U?5OY=3V!V?"_P^GOMEYJZR6]NK\6S*
M5>0#KGNHSCW(STX->I1QI#$D42*D:*%55&`H'0`=A0!!8Z?::9;+;V5O'!$/
MX4&,G`&2>YP!R>:Y/XG_`/(M6W_7XO\`Z`]=K7%?$_\`Y%JV_P"OQ?\`T!Z0
M'DU%%%,`HHHH`*]K\!?\B7I__;3_`-&-7BE>U^`O^1+T_P#[:?\`HQJ`.CHH
MHI`%%%%`!1110`4444`%%%%`!1110`4444`>!Z]I,NBZS<V4D<B(KDPF3!+Q
MY.ULC@Y'ZY':LVO<?$?A6P\1Q*9]T-S&I$<\8&0.>&'=<\X_(C)KR_4O!&OZ
M:QS9-<Q[@HDM?W@)(ST'S`=LD#^5,#GJ*TO^$>UO_H#ZA_X#/_A1_P`(]K?_
M`$!]0_\``9_\*`,VBM+_`(1[6_\`H#ZA_P"`S_X4?\(]K?\`T!]0_P#`9_\`
M"@#-HK2_X1[6_P#H#ZA_X#/_`(4?\(]K?_0'U#_P&?\`PH`S:*TO^$>UO_H#
MZA_X#/\`X4?\(]K?_0'U#_P&?_"@#-HK2_X1[6_^@/J'_@,_^%'_``CVM_\`
M0'U#_P`!G_PH`S:*TO\`A'M;_P"@/J'_`(#/_A1_PCVM_P#0'U#_`,!G_P`*
M`,VBM+_A'M;_`.@/J'_@,_\`A1_PCVM_]`?4/_`9_P#"@#-HK2_X1[6_^@/J
M'_@,_P#A1_PCVM_]`?4/_`9_\*`,VBM+_A'M;_Z`^H?^`S_X4?\`"/:W_P!`
M?4/_``&?_"@#-HK2_P"$>UO_`*`^H?\`@,_^%'_"/:W_`-`?4/\`P&?_``H`
MS:*TO^$>UO\`Z`^H?^`S_P"%'_"/:W_T!]0_\!G_`,*`#P_;_:_$6FPF'SE:
MYCWQ[=P*A@6R/3&<^U>^5Y_X"\(7%A<'5=3@:*95`MHR_(##YF8#H<'`!Z<Y
M'2O0*0!1110`4444`?.-%=5XH\%W^D7=Q<6MNTVFEBZ/'EC$O)PPR3@`?>Z=
M.<G%<K3`****`"BBM#3=#U/5V`L+&:92Q7>%P@(&<%CP#CU/<4`>M^`O^1+T
M_P#[:?\`HQJZ.LW0-+_L;0K33RVYHD^<YR"Q)9L<#C)./:M*D`4444`%%%<]
MXR\0'0-$:2!U%Y.WEP`@'![M@GH!]>2N1S0!R_Q`\6/YKZ+I\R^7MQ=2(>2>
M\>>P]<>N.,$'SJBBF`4444`%%%.CC>:5(HD9Y'8*JJ,EB>@`[F@"6SL[B_NX
MK6UB:6>5MJ(O4G^@]^U>O^%_!=IX?V74K?:-0*8:0_=C)Z[!CTXR>?IDBF^"
MO"I\/VCW%UM:_N%&\``B)?[H/<^O;@>F3U5(`HHHH`****`"BBB@`HHHH`**
M**`"H+JSM;Z(17=M#<1AMP66,.`?7![\FIZ*`.,U+X:Z/=*39/-92;0``WF)
MG/)(;DG''WAV_'S_`%KPIJ^A9>ZM]]N/^7B'YD[=3U7D@<@9/3->YTV2-)HG
MBE17C=2K*PR&!Z@CN*`/G.BN^\;>"?L?F:KI47^C<M/;J/\`5>K*/[OJ.WTZ
M<#3`****`"BBB@`KW;PMJYUKP[:WDC*9]I2;#`G>O!)QC!/#8_VA7A->A_"R
M^VW.H:>S2'>BS(,_*N#M;\3N7\O84`>ET444@"BBB@#A?%'P^@OM]YI"QV]P
MJ<VRJ%20CICLIQGV)QTY->97EG<6%W+:W4313Q-M=&Z@_P!1[]Z^AZI:EI&G
MZQ`(=0M(YU'W2PPR\@\,.1T'0\T`?/U%>@:M\,+B-FDTFZ66,*3Y5P=KY`'`
M8#!).>NW''UKBK_2[_2Y?+OK2:W8L54R(0&(Z[3T(Z<CUI@5****`"BBB@`H
MHHH`****`"BI[6SNKZ4Q6EM-<2!=Q6*,N0/7`[<BNQT?X:ZC<RA]4=;.%6Y1
M6#R,..F.`",\Y/(Z4`<3'&\TJ11(SR.P5549+$]`!W-=QX?^'%S?(+C5WDLX
MC@K"H'F,",Y/7;R1P03UX%=YH?AC3/#ZL;*)C,Z[7GE;<[#.<>@'T`S@9SBM
MBD!6L=/M-,MEM[*WC@B'\*#&3@#)/<X`Y/-6:**`,WQ#_P`BUJO_`%YS?^@&
MO`Z^BKBWBN[:6WG7=%*AC=<D94C!&1[5X3K'A[4]"E*WULRQEL+,OS1MUQAO
M4X)P<'':@#+HHHI@%%%6[#2[_5)?+L;2:X8,%8QH2%)Z;CT`Z\GTH`].^&'_
M`"+5S_U^-_Z`E=K63X:T;^P="M[%C&TJY:5XUP&8G/XX&!D]@.G2M:D`4444
M`%%%%`'SC175>*/!=_I%W<7%K;M-II8NCQY8Q+R<,,DX`'WNG3G)Q7*TP"BB
MB@`HHK0TW0]3U=@+"QFF4L5WA<("!G!8\`X]3W%`'K?@+_D2]/\`^VG_`*,:
MNCK-T#2_[&T*TT\MN:)/G.<@L26;'`XR3CVK2I`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`'.>/?^1+U#_MG_Z,6O%*]Z\1Z4^M:!=Z?%(L<DJC:S#(
MR&#`'V.,9_G7BNI:'J>D,1?V,T*A@N\KE"2,X##@G'H>QI@9]%%%`!1110`5
M]'5X[X3\'ZAJ6H6MY<6WE:>CK(S3IQ*!@[0IZA@>O3&>O2O8J0!1110`4444
M`%%%%`!1110`4444`>?^)?AREPSW>B%8Y68L]LYPAXZ)QP<]CQSU`&*\UN+>
M>TG:&XADAE7&Z.12K#(SR#[5]%5FZSH6GZ];""_AW[,F.13AHR1C(/\`0Y'`
MR#B@#P.BNZU;X9ZA;O))ID\=U%U6.0[).O3^Z<#'.1GGBN,NK.ZL91%=VTUO
M(5W!98RA(]<'MP:8$%%%%`!1110`4444`%%%%`!16IIOAS6-64/9:?-)&5+"
M0C8A`.#AFP"<]L^OI7>:+\,[:#$NL3_:7_YXPDJ@Z]6X8]CQC!'>@#S_`$G1
M;_6[M;>Q@9SN`>0@[(P<\L>PX/UQQDUZIX:\#V&B*EQ<A;J_V@EW`*1L#GY`
M1P>G)YXXQDBNFM[>"T@6&WACAB7.V.-0JC)SP![U)2`****`"N*^)_\`R+5M
M_P!?B_\`H#UVM8_B?0QX@T26R#*DP820NV<*X]<=B"1WQG.#B@#PFBK=_I=_
MI<OEWUI-;L6*J9$(#$==IZ$=.1ZU4I@%%%%`!7M?@+_D2]/_`.VG_HQJ\ATW
M2-0UB<PZ?:23L/O%1A5X)Y8\#H>IYKV_0-+_`+&T*TT\MN:)/G.<@L26;'`X
MR3CVH`TJ***0!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!5:[T^RO]GVRSM[C9G9YT2OMSUQD<=!5FB@#-_X1[1?^@/I__@,G^%'_
M``CVB_\`0'T__P`!D_PK2HH`I6^C:7:3K-;Z;9PRKG;)'`JL,C'!`]*NT44`
M%%%%`!1110`5XAXSU9=7\37,T4F^WBQ#">,;5ZD$=06+$'T->K^*[]]-\+ZA
M=1;O,$>Q2K;2I8A0P/J-V?PKPF@`HHHI@%%%%`!7H?PX\-Q7&[6KR'<(WVVH
M8'&X=7QCG!P`<\$'N!7!V=J]]?6]I$5$D\BQ*6/`+'`S[<U[]I]C!IFGP65N
MN(H4"+P,GW..Y/)]S0!9HHHI`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`#9(TFB>*5%>-U*LK#(8'J".XKPOQ3I(T7Q%=6<:L(-P>'*D#8W(`SG('*Y
M_P!DU[M7FGQ4MXEN=,N`O[V1)(V;)Y52I`Q]6;\Z`//****8!1110`5U'P^N
M)8?&-K'&V%F21)!@<KM+8_-0?PKEZZ3P%_R.FG_]M/\`T6U`'M5%%%(`HHHH
M`****`"BBB@#"NO!OAZ\E$DNEPJP7;B(M$,?12!GGK6!=?"W3GB`M-0NHI-W
M+2A9!CTP`O/3G-=Y10!YI<?"N=8&-OJT<DO&U9("BGGN03CCVJC_`,*PUO\`
MY^M/_P"_C_\`Q%>LT4`>3?\`"L-;_P"?K3_^_C__`!%2V_PNU1IU%Q?6<<7.
MYH]SL..P(&>?>O5**`//;?X5P+.IN-6DDBYW+'`$8\=B2<<^U;5C\/\`P_9;
M2]O)=.K[PUQ(3Z<8&%(X[@]:ZBB@".WMX+2!8;>&.&)<[8XU"J,G/`'O4E%%
M`!1110`4444`%%%%`%"30M(FE>672K%Y'8LS-;H2Q/4DXY-,_P"$>T7_`*`^
MG_\`@,G^%:5%`&;_`,(]HO\`T!]/_P#`9/\`"M".-(8DBB14C10JJHP%`Z`#
ML*=10`4444`%%%%`!1110`56N]/LK_9]LL[>XV9V>=$K[<]<9''059HH`S?^
M$>T7_H#Z?_X#)_A1_P`(]HO_`$!]/_\``9/\*TJ*`*$>A:1#*DL6E6*2(P96
M6W0%2.A!QP:OT44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`4)-"TB:5Y9=*L7D=BS,UNA+$]23CDTS_`(1[1?\`H#Z?_P"`R?X5I44`
M9O\`PCVB_P#0'T__`,!D_P`*LVFGV5AO^QV=O;[\;_)B5-V.F<#GJ:LT4`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!4=Q;P7<#0W$,<T38W1R*&4X.
M>0?>I**`.<O_``+X?O\`S&^Q?9Y7Q\]NQ3;C'1?NCIZ?KS6%=?"RU>4&TU2:
M*/;RLL0D.?7(*\=.,5Z!10!Y;=?"W44E`M-0M98]O+2AHSGTP`W'3G-0?\*P
MUO\`Y^M/_P"_C_\`Q%>LT4`>3?\`"L-;_P"?K3_^_C__`!%6;3X67K[_`+9J
M5O#C&SR4:3/KG.W';UKU"B@#@[7X6Z<D1%WJ%U+)NX:(+&,>F"&YZ\YKI+#P
MIH6FR^;:Z;")-P8-)F0J1T*EB=I^E;%%`!1110`4444`%%%%`!1110`50DT+
M2)I7EETJQ>1V+,S6Z$L3U)..35^B@#-_X1[1?^@/I_\`X#)_A3X]"TB&5)8M
M*L4D1@RLMN@*D="#C@U?HH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`.#^*5TB:
M18VA#>9+.95..,*I!S[_`#C]:\MKT#XIW2/?:=:`-YD4;RL<<88@#'O\A_2O
M/Z8!1110`4444`=9\.;3[3XMCEW[?LT+RXQG=D;,>WW\_A7L5>6_"V!&U>^G
M,RB1(`BQ=V#,"6'/0;0/^!#\?4J0!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%><?%;_F$?]MO_9*]'KROXGWWG:S:62M&RV\)<[3E@SGD'\%4
M_C[T`<+1113`****`"ND\!?\CII__;3_`-%M7-UU7P[M7N/%\$J%0MO')*^3
MR05V<>^7'ZT`>R4444@"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@#R;XG_\`(RVW_7FO_H;UQ5>C_%;_`)A'_;;_`-DKSBF`4444`%%%%`'8
M_#2XBA\4O'(V&FMG2,8/+95L?DI/X5Z[7SUI]]/IFH07MNV)87#KR<'V..Q'
M!]C7OFGWT&IZ?!>V[9BF0.O(R/8X[@\'W%("S1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`-DD2&)Y975(T4LS,<!0.I)["O`]<U(ZOK=Y?DL5FD
M)3<`"$'"@XXR%`%=S\0/%B>4^BZ?,WF;L74B'@#O'GN?7'ICG)`\VI@%%%%`
M!1110`5Z/\++#_D(:B\7]V".3=_P)QC/^YSCZ=Z\XKW/PEIG]D^&;*W9-LK)
MYLN8]C;FYPP]0"%Y_N_A0!MT444@"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@#D_B-:?:?"4DN_;]FF27&,[LG9CV^_G\*\=KZ'O+5+ZQN+2
M4L(YXVB8J>0&&#CWYKP'4+&?3-0GLKA<2PN4;@X/N,]B.1[&F!6HHHH`****
M`"NF\)>+7\-RRQ2PM/:3,I90^"A'5E'0G'4<9P.1BN9HH`^A[.\M[^TBNK65
M98)5W(Z]"/Z'V[5/7@.DZU?Z)=K<6,[(=P+QDG9(!GAAW')^F>,&O0M)^)ME
M<,L6J6S6K;1F:,ET)P<DC&0,XP!NZ^V:0'>454L-4L-4B\RQNX;A0H9A&X)4
M'IN'4'KP?2K=`!1110`4444`%%%%`!1110`45'<7$%I`TUQ-'#$N-TDC!5&3
MCDGWKE-6^(FCV"LEF6OYPQ7;'\J`@@<N1R.N"`<X_&@#KZ\]\7>/HE@:PT2?
M?(V5ENDR`@SC"'N3_>'`'3DY')>(/%VI>('*2/Y%H,@6\3':1G(W?WCP/;C@
M"L"@`HHHI@%%%%`!113HXWFE2*)&>1V"JJC)8GH`.YH`Z+P3H?\`;7B"/S8]
MUI;8EFR,AL?=4\$<GL>H#5[56%X3T%-!T2*)HU6[E4/<MCDM_=)R>%SCCCJ>
MYK=I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5YU\
M2O#Y=4URW1<(HCNN0#C("MTY/.#S_=XP#7HM-DC2:)XI45XW4JRL,A@>H([B
M@#YSHKK_`!EX-?0Y6O;)6?37;D=3`3V/JOH?P/.">0I@%%%%`!1110`4444`
M.CD>&5)8G9)$8,K*<%2.A![&MNU\9>(;.(QQ:I,REMV90LIS]6!...E85%`'
M:V_Q.UF/REFM[.95P'.QE9P.O(.`3],>U:7_``M;_J"_^37_`-A7G%%`'J5K
M\4M.>(F[T^ZBDW<+$5D&/7)*\]>,5/\`\+/T7_GUU#_OVG_Q=>344`>L_P#"
MS]%_Y]=0_P"_:?\`Q=9\GQ502N(M'9HPQVLUQM)'8D;3@^V37FU%`'?7?Q3O
M7V?8]-MX<9W^<[29],8VX[^M9-]\0/$%[N"7$=JC)L*V\8'KSDY8'GL1TKEZ
M*`)[J\NKZ42W=S-<2!=H:60N0/3)[<FH***`"BBB@`HHHH`****`"O4O`W@U
M].:/5]15DNRI\B`\&,$8);_:()X[9YYZ5O"?P_3RHM0UJ-O,W!X[0]`/^F@[
MGH=OMSG)`]%I`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`#9(TFB>*5%>-U*LK#(8'J".XKR_P`2_#NXM6>ZT8-<0%BQ
MMOXXQC/!)^<=>.O3KR:]2HH`^<:*]M\0>#=,U]GGD5H+PK@7$?4X!`W#H1T]
M#P!D5YUJW@'6]->1H8/MMNO(D@Y8C.!E/O9Z$XR!GK3`Y>BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BKNFZ1J&L3F'3[22=A]XJ,*O!/
M+'@=#U/-=YH_PP"2B36+I9%5N(;8G##CJQ`..HP`/K0!PVDZ+?ZW=K;V,#.=
MP#R$'9&#GECV'!^N.,FO5/#7@>PT14N+D+=7^T$NX!2-@<_(".#TY//'&,D5
MT=G9V]A:16MK$L4$2[41>@']3[]ZGI`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`%#4M#TS5U(O[
M&&9BH7>5PX`.<!AR!GT/<UR&I_#"TEW2:9>20-\Q$4PWKG^%01@@=LG<?Z]]
M10!XS??#_P`066XI;QW2*F\M;R`^O&#AB>.P/6L"[T^]L-GVRSN+??G9YT3)
MNQUQD<]17T+10!\XT5]`W&C:7=SM-<:;9S2MC=))`K,<#')(]*S;CP3X<N9V
MFDTN,,V,B-VC7ICA5(`_*F!XA17H?CSPSI&C:'!<:?:>3*URL9;S';*E6.,$
MGN!7GE`!1110`4444`%%>NZ-X*\/7>AZ?<3Z?NEEMHY';SI!EBH).`WK6S:^
M%-`LXC'%I-JREMV94\TY^K9...E`'A-;%KX4U^\E,<6DW2L%W9E3RACZM@9Y
MZ5[E;V\%I`L-O#'#$N=L<:A5&3G@#WJ2D!Y78_##4IMK7MY;VRE,X0&1@W'R
MD<#UY!/2NNTWP%H&G,'-LUW(&)#73;P`1C&T`*1]1_2NFHH`;'&D,211(J1H
MH5548"@=`!V%.HHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
>HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
